Fused 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer

Fused ring-fused 2-amino-3-cyanothiophenes provide effective inhibition of KRAS mutations in cancers, addressing the lack of suitable inhibitors with enhanced metabolic stability and permeability, thereby controlling uncontrolled cell proliferation.

JP2024543982APending Publication Date: 2024-11-26BOEHRINGER INGELHEIM INT GMBH +1

Patent Information

Application Number
JP2024532554
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-01
Filing Date
2022-11-30
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Current treatments for cancers driven by KRAS mutations, particularly those at position 12 or 13, or amplified wild-type KRAS, lack effective inhibitors with desirable pharmacological properties such as metabolic stability, plasma protein binding, and permeability.

Method used

Development of fused ring-fused 2-amino-3-cyanothiophenes and derivatives that act as selective inhibitors of KRAS, targeting mutations like G12D, G12V, or amplified wild-type KRAS, with improved metabolic stability, solubility, and permeability.

Benefits of technology

The compounds demonstrate anti-tumor activity by inhibiting KRAS mutations, effectively controlling uncontrolled cell proliferation in cancers, including drug-resistant cases, and offer improved pharmacokinetic properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543982000001_ABST
    Figure 2024543982000001_ABST
Patent Text Reader

Abstract

The present invention relates to a compound represented by formula (I): 1a , R 1b , R 2a , R 2b , Z, R 3 ~R 5 , A, p, L, U, V and W have the meanings given in the claims and the specification, their use as inhibitors of mutant Ras family proteins, pharmaceutical compositions and preparations containing such compounds, and their use as medicinal / medical uses, in particular as agents for the treatment and / or prevention of neoplastic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to a compound of formula (I): [ka] [In the formula, R 1a , R 1b , R 2a , R 2b , Z, R 3 ~R 5 , A, p, L, U, V and W have the meanings given in the claims and the specification. The present invention relates to fused 2-amino-3-cyanothiophenes and derivatives of the formula: [Background technology]

[0002] 2. Background of the Invention V-Ki-ras2 Karsten rat sarcoma viral oncogene homolog (KRAS) is a small GTPase of the Ras family of proteins that exists in cells in either a GTP-bound or GDP-bound state (McCormick et al., J. Mol. Med. (Berl)., 2016, 94(3):253-8; Nimnual et al., Sci. STKE., 2002, 2002(145):pe36). Binding of GTPase-activating proteins (GAPs) such as NF1 increases the GTPase activity of Ras family proteins. Binding of guanine nucleotide exchange factors (GEFs) such as SOS1 (Son of Sevenless 1) promotes the release of GDP from Ras family proteins, allowing GTP binding (Chardin et al., Science, 1993, 260(5112):1338-43). When in the GTP-bound state, Ras family proteins are active and engage effector proteins, including C-RAF and phosphoinositide 3-kinase (PI3K), to promote the RAF / mitogen or extracellular signal-regulated kinase (MEK / ERK) pathway, the PI3K / AKT / mammalian target of rapamycin (mTOR) pathway, and the RalGDS (Ral guanine nucleotide dissociation stimulator) pathway (McCormick et al., J. Mol. Med. (Berl)., 2016, 94(3):253-8; Rodriguez-Viciana et al., Cancer Cell. 2005, 7(3):205-6). These pathways affect diverse cellular processes such as proliferation, survival, metabolism, motility, angiogenesis, immunity and growth (Young et al., Adv. Cancer Res., 2009, 102:1-17; Rodriguez-Viciana et al., Cancer Cell. 2005, 7(3):205-6).

[0003] Cancer-associated mutations in Ras family proteins suppress their intrinsic and GAP-induced GTPase activity, leading to an increase in the population of GTP-bound / active mutant Ras family proteins (McCormick et al., Expert Opin. Ther. Targets., 2015, 19(4):451-4; Hunter et al., Mol. Cancer Res., 2015, 13(9):1325-35). This, in turn, leads to sustained activation of effector pathways downstream of mutant Ras family proteins (e.g., RAF / MEK / ERK, PI3K / AKT / mTOR, RalGDS pathways). KRAS mutations (e.g., amino acids G12, G13, Q61, A146) are found in a wide variety of human cancers, including lung, colon, and pancreatic cancers (Cox et al., Nat. Rev. Drug Discov., 2014, 13(11):828-51). Additionally, alterations (e.g., mutations, overexpression, gene amplification) in Ras family proteins / Ras genes have been described as a resistance mechanism to cancer therapeutics such as the EGFR antibodies cetuximab and panitumumab (Leto et al., J. Mol. Med. (Berl). 2014 Jul;92(7):709-22) and the EGFR tyrosine kinase inhibitor osimertinib / AZD9291 (Ortiz-Cuaran et al., Clin. Cancer Res., 2016, 22(19):4837-47; Eberlein et al., Cancer Res., 2015, 7 5(12):2489-500).

[0004] In some oncology indications, such as gastric, esophagogastric and esophageal cancer, prominent amplification of the wild-type (WT) KRAS proto-oncogene acts as a driver mutation such that tumor models with this genotype are KRAS-dependent in vitro and in vivo (Wong et al. Nat Med., 2018, 24(7):968-977). In contrast, non-amplified KRAS WT cell lines are KRAS-independent unless they harbor secondary mutations in the gene that indirectly cause KRAS activation (Meyers et al., Nat Genet., 2017, 49:1779-1784). Based on these data, a therapeutic window is expected for KRAS-targeting agents with KRAS WT-targeting activity.

[0005] For example, genetic mutations affecting codon 12 of KRAS replace the naturally occurring glycine residue at this position with a different amino acid, such as aspartic acid (G12D mutation or KRAS G12D), cysteine ​​(G12C mutation or KRAS G12C), or valine (G12V mutation or KRAS G12V), among others. Similarly, mutations within codons 13, 61, and 146 of KRAS are also commonly found in the KRAS gene. Overall, KRAS mutations are detectable in 35% of lung cancers, 45% of colorectal cancers, and up to 90% of pancreatic cancers (Herdeis et al., Curr Opin Struct Biol., 2021, 71:136-147).

[0006] In general, binders / inhibitors of wild-type or mutated KRAS (eg, G12D, G12V and G12C) are expected to exert anti-cancer effects. Summary of the Invention [Problem to be solved by the invention]

[0007] Thus, there is a need to develop new compounds that are effective in treating cancers mediated by KRAS, particularly KRAS mutated at position 12 or 13 and / or wild-type amplified KRAS mediated cancers, and that also have desirable pharmacological properties, including, but not limited to, metabolic stability, plasma protein binding, solubility and permeability. [Means for solving the problem]

[0008] Detailed Description of the Invention It has now been surprisingly discovered that a compound of formula (I): [ka] [In the formula, R 1a , R 1b , R 2a , R 2b , Z, R 3 ~R 5 , A, p, L, U, V and W have the meanings given herein below. It has been found that the compound represented by the formula (I) acts as an inhibitor of KRAS and is involved in the control of cell proliferation. Therefore, the compound according to the present invention can be used, for example, in the treatment of diseases characterized by excessive or abnormal cell proliferation.

[0009] Surprisingly, it has been found that the compounds described herein have antitumor activity and are useful for controlling the uncontrolled cell proliferation caused by malignant disease.This antitumor activity is believed to be derived in particular from the inhibition of KRAS mutated at position 12 or 13, preferably G12D, G12V or G12S mutant KRAS, or from the inhibition of WT KRAS, especially amplified KRAS WT.Advantageously, the compounds can be selective for certain KRAS mutants, preferably KRAS G12D, or can be effective against a population of KRAS mutants, including amplified KRAS wild type.

[0010] In addition, compounds of the present invention advantageously possess desirable pharmacological properties, including, but not limited to, metabolic stability, plasma protein binding, solubility and permeability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] Thus, in a first aspect, the present invention provides a compound of formula (I): [ka] [In the formula, R 1a and R 1b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 selected from the group consisting of cycloalkyl and 3-5 membered heterocyclyl; R 2a and R 2b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 selected from the group consisting of cycloalkyl and 3-5 membered heterocyclyl; and / or, optionally, R 1a or R 1b One of the two and R 2a or R 2b together with the carbon atom to which they are attached form a cyclopropane ring; Z is -(CR 6a R 6b ) n - and; Each R 6a and R 6b are independently hydrogen, C1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 selected from the group consisting of cycloalkyl and 3-5 membered heterocyclyl; Or R 6a and R 6b together with the carbon atoms to which they are attached form a cyclopropane ring; n is selected from the group consisting of 0, 1 and 2; L is -O-, -S- and -N(R 7 )-(wherein, R 7 is hydrogen or C 1-6 alkyl; R 3 is C 1-6 Alkyl, C 1-6 alkoxy, 5- to 10-membered heteroaryl, and 3- to 11-membered heterocyclyl, wherein C 1-6 Alkyl, 5-10 membered heteroaryl, C 1-6 All alkoxy and 3- to 11-membered heterocyclyl are optionally and independently selected from the same or different halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, -C(O)OC 1-6 Alkyl, C 3-5 Cycloalkyl, or -N(C 1-4 substituted by 3-11 membered heterocyclyl optionally substituted with alkyl); W is nitrogen (-N=) or -CH=; V is nitrogen (-N=) or -CH=; U is nitrogen (-N=) or -C(R 11 )=; R 11 is hydrogen, halogen and C 1-4 alkoxy; Ring A is a ring selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, and triazole; Each R 4 If present, independently, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, Cyano-C 1-6 Alkyl, halogen, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, -CN, C 3-5 selected from the group consisting of cycloalkyl and 3-5 membered heterocyclyl; p is selected from the group consisting of 0, 1, 2 and 3; R 5 is one or more identical or different, C 1-6 Alkyl, C 1-6 3- to 11-membered heterocyclyl optionally substituted with alkoxy or 5- to 6-membered heterocyclyl, where C 1-6 Alkyl is optionally substituted with cyclopropyl; Or R 5 is substituted with 3-11 membered heterocyclyl -OC 1-6 alkyl, where the 3- to 11-membered heterocyclyl is one or more of the same or different R 12 and optionally substituted with Each R 12 is C 1-6 Alkyl, C 1-6 selected from the group consisting of alkoxy, halogen and 3- to 11-membered heterocyclyl. or a salt thereof.

[0012] In another aspect, the present invention provides a compound comprising R 1a and R 1b are each independently hydrogen and C 1-4 The present invention relates to a compound of formula (I), or a salt thereof, wherein the compound is selected from the group consisting of alkyl.

[0013] In another aspect, the present invention provides a compound comprising R 2a and R 2b and are both independently selected from the group consisting of hydrogen and halogen, or a salt thereof.

[0014] In another aspect, the present invention provides a compound comprising R 1a and R 1b and R are each independently selected from the group consisting of hydrogen and methyl, or a salt thereof.

[0015] In another aspect, the present invention provides a compound comprising R 2a and R 2b and are both independently selected from the group consisting of hydrogen and fluorine, or a salt thereof.

[0016] In another aspect, the present invention provides a compound comprising R 1a , R 1b , R 2a and R 2b is hydrogen, or a salt thereof.

[0017] In another embodiment, the present invention relates to a compound of formula (I) or a salt thereof, wherein n is 0.

[0018] In another aspect, the present invention provides a method for producing a composition comprising: n is 1; Each R 6a and R 6b are independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The present invention relates to a compound represented by formula (I), or a salt thereof, wherein R is selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl.

[0019] In another embodiment, the present invention relates to a compound of formula (I) or a salt thereof, wherein Z is -CH2-.

[0020] In another aspect, the present invention provides a method for producing a composition comprising: n is 2; Each R 6a and R 6b are independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The present invention relates to a compound represented by formula (I), or a salt thereof, wherein R is selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl.

[0021] In another embodiment, the present invention relates to a compound of formula (I) or a salt thereof, wherein p is 0.

[0022] In another aspect, the present invention provides a compound of formula (I * ) or a salt thereof. [ka] [In the formula, R 1a , R 1b , R 2a , R 2b , R 3 , R 4 , R 5 , Z, L, U, V, W, ring A and p are as defined herein above or below.

[0023] In another aspect, the present invention relates to a compound of formula (Ia) or a salt thereof. [ka] [In the formula, A, V, U, W, L, R 3 and R 5 are as defined herein.

[0024] In another aspect, the present invention relates to a compound of formula (Ib) or a salt thereof. [ka] [In the formula, A, V, U, W, L, R 3 and R 5 are as defined herein.

[0025] In another embodiment, the present invention relates to the compound of the present invention, or a salt thereof, wherein ring A is a ring selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, isoxazole, isothiazole and triazole.

[0026] In another aspect, the present invention relates to a compound wherein ring A is [ka] The present invention relates to a compound of the present invention, or a salt thereof, selected from the group consisting of:

[0027] In another embodiment, the present invention relates to a compound of the present invention, or a salt thereof, wherein Ring A is isoxazole or isothiazole.

[0028] In another aspect, the present invention relates to a compound wherein ring A is [ka] The present invention relates to a compound of the present invention, or a salt thereof, selected from the following:

[0029] In another aspect, the present invention relates to a compound of formula (Ic), or a salt thereof: [ka] [In the formula, V, U, W, L, R 3 and R 5 are as defined herein.

[0030] In another aspect, the present invention relates to a compound of formula (Id), or a salt thereof: [ka] [In the formula, V, U, W, L, R 3 and R 5 are as defined herein.

[0031] In another aspect, the present invention relates to a compound of formula (Ie), or a salt thereof: [ka] [In the formula, V, U, W, L, R 3 and R 5 are as defined herein.

[0032] In another aspect, the present invention relates to a compound represented by formula (If), or a salt thereof: [ka] [In the formula, V, U, W, L, R 3 and R 5 are as defined herein.

[0033] In another aspect, the present invention provides a compound represented by formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0034] In another aspect, the present invention provides a method for producing a composition comprising: W is nitrogen (-N=); V is nitrogen (-N=); U is =C(R 11 )-and; R 11 However, hydrogen, halogens and C 1-4alkoxy, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0035] In another aspect, the present invention provides a method for producing a composition comprising: W is -CH=; V is nitrogen (-N=); U is =C(R 11 )-and; R 11 However, hydrogen, halogens and C 1-4 alkoxy, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0036] In another aspect, the present invention provides a method for producing a composition comprising: V is -CH=; W is nitrogen (-N=); U is =C(R 11 )-and; R 11 However, hydrogen, halogens and C 1-4 alkoxy, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0037] In another aspect, the present invention provides a method for producing a composition comprising: R 11 is selected from hydrogen, fluorine, chlorine and -O-CH3, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0038] In another aspect, the present invention provides a method for producing a composition comprising: V is nitrogen (-N=); W is -CH=; U is nitrogen (-N=), *The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0039] In another aspect, the present invention provides a method for producing a composition comprising: W is nitrogen (-N=); V is -CH=; U is nitrogen (-N=), * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0040] In another aspect, the present invention provides a method for producing a composition comprising: W is -CH=; V is -CH=; U is nitrogen (-N=), * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0041] In another aspect, the present invention provides a method for producing a composition comprising: W is nitrogen (-N=); V is nitrogen (-N=); U is nitrogen (-N=), * The present invention relates to a compound represented by the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.

[0042] In another aspect, the present invention provides a method for producing a composition comprising: R 5 may contain one or more identical or different C 1-6 Alkyl, C 1-6 6- to 11-membered heterocyclyl optionally substituted with alkoxy or 5- to 6-membered heterocyclyl, where C 1-6 The alkyl group of formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0043] In another aspect, the present invention provides a method for producing a composition comprising: R 5 may contain one or more identical or different C 1-4 7-membered heterocyclyl optionally substituted with alkyl, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0044] In another aspect, the present invention provides a method for producing a composition comprising: R 5 is substituted with 5-8 membered heterocyclyl -OC 1-6 alkyl, wherein the 5- to 8-membered heterocyclyl is one or more of the same or different R 12 and optionally substituted with Each R 12 But, C 1-6 Alkyl, C 1-6 alkoxy, halogen and 5-membered heterocyclyl, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0045] In another aspect, the present invention provides a method for producing a composition comprising: R 5 but, [ka] Formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0046] In another aspect, the present invention provides a method for producing a composition comprising: R 5 but, [ka] Formula (I), (I *The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0047] In another aspect, the present invention provides a method for producing a composition comprising: R 5 but, [ka] Formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0048] In another aspect, the present invention provides a method for producing a composition comprising: R 5 but, [ka] Formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0049] In another aspect, the present invention provides a method for producing a composition comprising: R 5 but, [ka] Formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0050] In another aspect, the present invention provides a compound comprising R 5 but, [ka] Formula (I), (I *The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0051] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6 Alkyl, C 1-6 alkoxy, 5- to 10-membered heteroaryl, and 3- to 11-membered heterocyclyl, wherein C 1-6 Alkyl, 5-10 membered heteroaryl, C 1-6 Alkoxy and 3- to 11-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The formula (I), (I * The present invention relates to a compound represented by the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.

[0052] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6 Alkyl, C 1-6 alkoxy, 5- to 6-membered heteroaryl, and 4- to 5-membered heterocyclyl, wherein C 1-6 Alkyl, 5-6 membered heteroaryl, C 1-6 Alkoxy and 4- to 5-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, -C(O)OC 1-6 Alkyl, C 3-5 Cycloalkyl, or -N(C 1-4 3 to 11 membered heterocyclyl optionally substituted with alkyl)2, *The present invention relates to a compound represented by the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.

[0053] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6 Alkyl, C 1-6 alkoxy, 5- to 6-membered heteroaryl, and 4- to 5-membered heterocyclyl, wherein C 1-6 Alkyl, 5-6 membered heteroaryl, C 1-6 Alkoxy and 4- to 5-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The formula (I), (I * The present invention relates to a compound represented by the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.

[0054] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6 Alkyl, C 1-6 is selected from the group consisting of alkoxy, 5- to 6-membered heteroaryl, and 4- to 5-membered heterocyclyl, each of which independently contains 1 or 2 nitrogen or 1 oxygen heteroatoms, where C 1-6 Alkyl, 5-6 membered heteroaryl, C 1-6 Alkoxy and 4- to 5-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, -C(O)OC 1-6 Alkyl, C 3-5 Cycloalkyl, or -N(C 1-43 to 11 membered heterocyclyl optionally substituted with alkyl)2, * The present invention relates to a compound represented by the formula (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.

[0055] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6 Alkyl, C 1-6 is selected from the group consisting of alkoxy, 5- to 6-membered heteroaryl, and 4- to 5-membered heterocyclyl, each of which independently contains 1 or 2 nitrogen or 1 oxygen heteroatoms, where C 1-6 Alkyl, 5-6 membered heteroaryl, C 1-6 Alkoxy and 4- to 5-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij ... * The present invention relates to a compound represented by the formula (Ib), (Ic), (Id), (Ie) or (If) or a salt thereof.

[0056] In another aspect, the present invention provides a method for producing a composition comprising: R 3 is 4-7 membered heterocyclyl or C 3-5 Cycloalkyl-substituted C 1-4 alkyl, where the 4- to 7-membered heterocyclyl is -N(C 1-4 Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (Ig), (Ih), (Ii), (Ij ... * The present invention relates to a compound represented by the formula (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0057] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6selected from the group consisting of alkyl, -CH(CH3)CH2-O-CH3, -(CH2)2-O-CH3, -(CH2)2-OH and -(CH2)2-N-(CH3)2; or R 3 but, [ka] is a ring selected from the group consisting of wherein each of these rings optionally and independently comprises one or more of the same or different halogens, C 1-6 Alkyl, -OH, -NH2, -NH(C 1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 The formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0058] In another aspect, the present invention provides a method for producing a composition comprising: R 3 But, C 1-6 Alkyl, -CH(CH3)CH2-O-CH3, -(CH2)2-O-CH3, -(CH2)2-OH, -(CH2)2-N-(CH3)2, [ka] Formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a salt thereof.

[0059] In another aspect, the present invention provides a method for producing a composition comprising: -L- is -O-; R 3 is a 4- to 5-membered heterocyclyl containing one or two nitrogen heteroatoms, wherein the 4- to 5-membered heterocyclyl is selected from the group consisting of one or more of the same or different halogen, C 1-6 Alkyl, -OH, -NH2, -NH(C1-4 alkyl), -N(C 1-4 Alkyl)2, C 3-5 optionally substituted with cycloalkyl or 3- to 11-membered heterocyclyl; W is nitrogen (-N=); V is nitrogen (-N=); U is -CH=; R 5 is substituted with 5-8 membered heterocyclyl -OC 1-6 alkyl, wherein the 5- to 8-membered heterocyclyl is one or more of the same or different R 12 and optionally substituted with Each R 12 But, C 1-6 Alkyl, C 1-6 The present invention relates to a compound represented by formula (Ic), (Id), (Ie) or (If), or a salt thereof, wherein: R is selected from the group consisting of alkoxy, halogen and 5-membered heterocyclyl.

[0060] Preferred embodiments of the compound represented by formula (I) according to the present invention are exemplified compounds I-1 to I-7 and II-1 to II-31 and any subset thereof.

[0061] It is to be understood that any two or more aspects and / or preferred embodiments of formula (I) or subformulas thereof can be combined in any manner that results in a chemically stable structure to obtain further aspects and / or preferred embodiments of formula (I) or subformulas thereof.

[0062] The present invention further relates to a compound represented by the formula (I), * The present invention relates to hydrates, solvates, polymorphs, metabolites, derivatives, stereoisomers and prodrugs of the compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).

[0063] The present invention further relates to a compound represented by the formula (I), * The present invention relates to a hydrate of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).

[0064] The present invention further relates to a compound represented by the formula (I), * The present invention relates to a solvate of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).

[0065] For example, the formula (I), (I * The compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof) are potential prodrugs in which the ester is cleaved under physiological conditions and are also part of the present invention.

[0066] The present invention further relates to a compound represented by the formula (I), * The present invention relates to a pharma- ceutically acceptable salt of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).

[0067] The present invention further relates to a compound represented by the formula (I), (I * The present invention relates to a pharma- ceutically acceptable salt of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof).

[0068] Pharmaceutical Compositions A further object of the present invention is to provide a compound of formula (I), * and one or more pharma- ceutical compositions comprising a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutical acceptable salt thereof, and one or more pharma- ceutical acceptable excipients.

[0069] In one embodiment, the pharmaceutical composition optionally comprises one or more other pharmacologically active substances, which may be pharmacologically active substances or combination partners as defined herein.

[0070] The compound represented by formula (I), (I *Suitable pharmaceutical compositions for administering a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) will be apparent to those skilled in the art and include, for example, tablets, pills, capsules, suppositories, lozenges, troches, solutions, suspensions, particularly solutions for injection (sc, iv, im) and infusion (injectables), suspensions or other mixtures, elixirs, syrups, sachets, emulsions, inhalants or dispersible powders. Compounds (I), (I * The content of (Ia), (Ib), (Ic), (Id), (Ie) or (If) should be in the range of 0.1 to 90% by weight, preferably 0.5 to 50% by weight, of the total composition, i.e., an amount sufficient to achieve the dosage range specified below. The specified dose may be given several times a day as needed.

[0071] Suitable tablets include, for example, those of formula (I), * The tablet may be obtained by mixing the compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) with known pharma- ceutically acceptable excipients, such as inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and / or lubricants. The tablet may also comprise several layers.

[0072] Coated tablets can be prepared by coating a core, which is prepared in the same manner as for tablets, with excipients usually used for tablet coatings, such as collidone or shellac, gum arabic, talc, titanium dioxide or sugar, if appropriate. The core may consist of multiple layers to achieve delayed release or to prevent incompatibilities. Similarly, the tablet coating may consist of multiple layers to achieve delayed release, optionally using the excipients mentioned above for tablets.

[0073] One or more of (I), (I *Syrups or elixirs containing (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a combination with one or more other pharma- ceutically active substances may additionally contain excipients such as sweeteners, such as saccharin, cyclamate, glycerol or sugar, and flavour enhancers, for example flavourings such as vanillin or orange extract. They may also contain excipients such as suspension adjuvants or thickeners, for example sodium carboxymethylcellulose, wetting agents, for example condensation products of fatty alcohols with ethylene oxide, or preservatives, such as p-hydroxybenzoates.

[0074] Solutions for injection and infusion are prepared in the usual way, for example with the addition of excipients such as isotonic agents, preservatives such as p-hydroxybenzoates, or stabilizers such as alkali metal salts of ethylenediaminetetraacetic acid, and optionally with the use of emulsifiers and / or dispersants, but where water is used as diluent, for example with organic solvents, optionally as solvating or dissolving agents, and transferred into injection vials or ampoules or infusion bottles.

[0075] One or more of formula (I), (I * Capsules containing a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a combination with one or more other pharma- ceutically active substances can be prepared, for example, by mixing the compound / active substances with an inert excipient such as lactose or sorbitol and filling them into gelatin capsules.

[0076] Suitable suppositories can be prepared by mixing with excipients provided for this purpose, such as, for example, neutral fats or polyethylene glycol or its derivatives.

[0077] Excipients that may be used include, for example, water, pharma- ceutically acceptable organic solvents such as paraffins (e.g., petroleum fractions), vegetable oils (e.g., peanut oil or sesame oil), monofunctional or polyfunctional alcohols (e.g., ethanol or glycerol), carriers such as natural mineral powders (e.g., kaolin, clay, talc, chalk), synthetic mineral powders (e.g., highly disperse silicic acid and silicates), sugars (e.g., sucrose, lactose and glucose), emulsifiers (e.g., lignin, spent sulfite liquor, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g., magnesium stearate, talc, stearic acid and sodium lauryl sulfate).

[0078] The pharmaceutical composition is administered by conventional methods, preferably by oral or transdermal route, most preferably by oral route.For oral administration, tablets can of course contain additional excipients such as sodium citrate, calcium carbonate and dicalcium phosphate, apart from the above-mentioned excipients, together with various excipients such as starch, preferably potato starch, gelatin.Furthermore, lubricants such as magnesium stearate, sodium lauryl sulfate and talc can be used at the same time in the tableting process.In the case of aqueous suspensions, active substances can be combined with various flavor enhancers or colorants in addition to the above-mentioned excipients.

[0079] For parenteral use, solutions of the active substance and a suitable liquid excipient may be used.

[0080] Formula (I), (I * The applicable daily dose range of the compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) is usually 1 mg to 2000 mg, preferably 250 to 1250 mg.

[0081] However, the dosage may sometimes need to deviate from the specified amount depending on the body weight, age, route of administration, severity of the disease, individual response to the drug, the nature of its formulation and the time or interval at which the drug is administered (continuous or intermittent treatment with one or several doses per day). Thus, in some cases, it may be sufficient to use a dosage lower than the minimum dose given above, while in other cases, the upper limit may have to be exceeded. When administering larger amounts, it may be advisable to divide these into several smaller doses per day.

[0082] Thus, in a further aspect, the present invention provides at least one (preferably one) compound of formula (I), (I * The present invention relates to a pharmaceutical composition comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.

[0083] Formula (I), (I * The compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or pharma- ceutically acceptable salts thereof, and pharmaceutical compositions containing such compounds and salts, may also be co-administered, i.e., used in combination with other pharmacologically active substances, such as other anti-neoplastic compounds (e.g., chemotherapy) (see further below under Combination Treatments).

[0084] The elements of such combinations can be administered (subordinately or independently) in a manner that is conventional to those of skill in the art and that is used in monotherapy, for example, by oral, enteral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, transdermal or subcutaneous injection, or implant), nasal, vaginal, rectal or topical routes of administration, and can be formulated, either alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable excipients appropriate for each route of administration.

[0085] The combination may be administered in a single or divided daily dose that is therapeutically effective. The active components of the combination may be administered in such doses that are therapeutically effective in monotherapy, or in such doses that are less than the doses used in monotherapy but which, in combination, result in the desired (combined) therapeutically effective amount.

[0086] However, when the combination of two or more active substances or ingredients produces a synergistic effect, it is also possible to reduce the amount of one, more or all of the substances or ingredients administered while still achieving the desired therapeutic effect. This can be useful, for example, to avoid, limit or reduce any undesirable side effects associated with the use of one or more of the substances or ingredients when used in their usual amounts, while still ensuring the desired pharmacological or therapeutic effect.

[0087] Thus, in a further aspect, the present invention also provides a compound of formula (I), * The present invention relates to a pharmaceutical composition comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, and one or more (preferably, one or two, most preferably one) other pharmacologically active substances.

[0088] In a further aspect, the present invention also provides a compound represented by the formula (I), * The present invention relates to a pharmaceutical preparation comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, and one or more (preferably one or two, most preferably one) other pharmacologically active substances.

[0089] The pharmaceutical compositions to be administered simultaneously or in combination can also be provided in the form of a kit.

[0090] Thus, in a further aspect, the present invention also provides a method for producing a method for treating a pulmonary arthritis, comprising: Formula (I), (I *a first pharmaceutical composition or dosage form comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) and optionally one or more pharma- ceutically acceptable excipients; and A second pharmaceutical composition or dosage form comprising another pharmacologically active substance and optionally one or more pharma- ceutically acceptable excipients. The present invention relates to a kit comprising:

[0091] In one embodiment, such a kit comprises a third pharmaceutical composition or dosage form comprising an additional pharmacologically active agent and optionally one or more pharma- ceutically acceptable excipients.

[0092] Medical Use - Method of Treatment Indications – Patient population The present invention is directed to compounds which inhibit KRAS, preferably KRAS mutated at residue 12, such as inhibitors of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A and KRAS G12R, preferably inhibitors of KRAS G12C and / or KRAS G12D or inhibitors selective for KRAS G12D, as well as compounds which inhibit KRAS wild type, preferably amplified, KRAS mutated at residue 13, such as KRAS G13D, or KRAS mutated at residue 61, such as KRAS Q61H. In particular, the compounds of formula (I), (I * The compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) (including all embodiments thereof) are potentially useful in the treatment and / or prevention of diseases and / or conditions mediated by KRAS, preferably by KRAS mutated at residue 12, such as KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by amplification of KRAS wild type, or by KRAS mutated at residue 13, such as KRAS G13D, or by KRAS mutated at residue 61, such as KRAS Q61H.

[0093] Thus, in a further aspect, the present invention relates to a compound of formula (I), (I *The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0094] In a further aspect, the present invention relates to a compound of formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0095] In a further aspect, the present invention relates to a compound of formula (I), (I ) or (I ) for use in the treatment and / or prevention of diseases and / or conditions mediated by KRAS, preferably by KRAS mutated at residue 12, such as KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by amplification of KRAS wild type, or by KRAS mutated at residue 13, such as KRAS G13D. * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0096] In a further aspect, the present invention relates to a compound of formula (I), (I ) or (II ) in the manufacture of a medicament for the treatment and / or prevention of diseases and / or conditions mediated by KRAS, preferably by KRAS mutated at residue 12, such as KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by amplification of KRAS wild type, or by KRAS mutated at residue 13, such as KRAS G13D. * The present invention relates to the use of a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0097] In a further aspect, the present invention provides a compound according to the present invention, comprising a therapeutically effective amount of a compound represented by formula (I), *The present invention relates to a method for the treatment and / or prevention of a disease and / or condition mediated by KRAS, preferably by KRAS mutated at residue 12, such as KRAS G12C, KRAS G12D, KRAS G12V, more preferably G12D, or by amplification of KRAS wild type, or by KRAS mutated at residue 13, such as KRAS G13D, comprising administering to a human a compound of the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0098] In a further aspect, the present invention relates to a compound of formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0099] In a further aspect, the present invention relates to a compound of formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0100] In a further aspect, the present invention relates to a compound represented by formula (I), (I * The present invention relates to the use of a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0101] In a further aspect, the present invention provides a compound according to the present invention, comprising a therapeutically effective amount of a compound represented by formula (I), * The present invention relates to a method for treating and / or preventing cancer, comprising administering to a human a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0102] Preferably, the cancer as defined herein (above or below) comprises KRAS mutation.In particular, KRAS mutation comprises, for example, mutation of KRAS gene and KRAS protein, for example, overexpressed KRAS, amplified KRAS or KRAS, KRAS with mutated residue 12, KRAS with mutated residue 13, KRAS with mutated residue 61, KRAS with mutated residue 146, in particular KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G13C, KRAS G13D, KRAS G13V, KRAS Q61H, KRAS Q61E, KRAS Q61P, KRAS A146P, KRAS A146T, KRAS A146V.KRAS may present one or more of these mutations / mutations.

[0103] Preferably, the cancer as defined herein (above or below) comprises in addition to or instead of a KRAS mutation a BRAF mutation, in particular a class III BRAF mutation, such as a BRAF mutation as defined in Z. Yao, Nature, 2017, 548, 234-238.

[0104] Preferably, cancer as defined herein (above or below) comprises, in addition to or instead of a KRAS mutation, a mutation in a receptor tyrosine kinase (RTK), including an EGFR, MET and ERBB2 mutation.

[0105] In a further aspect, the present invention relates to a compound of formula (I), (I * or a pharmaceutically acceptable salt thereof, wherein the cancer comprises a KRAS mutation, and the KRAS mutation is preferably selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D; or amplification of KRAS wild type, amplification of the KRAS gene, or overexpression of KRAS.

[0106] In a further aspect, the present invention relates to a compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein the cancer comprises a KRAS mutation, said KRAS mutation is preferably selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D; or amplification of KRAS wild type, amplification of the KRAS gene or overexpression of KRAS.

[0107] In a further aspect, the present invention provides a compound according to the present invention, comprising a therapeutically effective amount of a compound represented by formula (I), * The present invention relates to a method for the treatment and / or prevention of cancer, comprising administering to a human a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein the cancer comprises a KRAS mutation, said KRAS mutation is preferably selected from the group consisting of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D; or amplification of KRAS wild type, amplification of the KRAS gene or overexpression of KRAS.

[0108] In a further aspect, the present invention relates to a compound of formula (I), (I * or a pharma- ceutically acceptable salt thereof, wherein the cancer comprises a KRAS G12D mutation.

[0109] In a further aspect, the present invention relates to a compound of formula (I), (I * or a pharma- ceutically acceptable salt thereof, wherein the cancer comprises a KRAS G12V mutation.

[0110] In a further aspect, the present invention relates to a compound of formula (I), (I * or a pharma- ceutically acceptable salt thereof, wherein the cancer comprises a KRAS G13D mutation.

[0111] In a further aspect, the present invention relates to a compound of formula (I), (I * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof, wherein the cancer involves wild-type amplified KRAS.

[0112] Another embodiment relates to a combination of a patient's KRAS status and a compound represented by formula (I), (I * The present invention is based on identifying a relationship between the potential sensitivity to treatment with a KRAS inhibitor, such as a compound represented by formula (I), (Ib), (Ic), (Id), (Ie) or (If). * Compounds of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) may then be advantageously used to treat patients with KRAS-dependent diseases that may be resistant to other therapies. This therefore means that compounds of formula (I), (I * The present invention provides the opportunity, methods and tools for selecting patients, particularly cancer patients, for treatment with a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If). The selection is based on whether the tumor cells to be treated have a wild type, preferably amplified KRAS, or a KRAS gene mutated at residue 12, preferably G12C, G12D or G12V, or a KRAS gene mutated at residue 13, preferably G13D. The status of the KRAS gene is therefore determined by the following formula (I), (I *(Ia), (Ib), (Ic), (Id), (Ie) or (If) may be advantageous in selecting treatment with a compound of formula (Ib), (Ic), (Id), (Ie) or (If).

[0113] According to one embodiment, the compound represented by formula (I), * 5. A method for selecting a patient for treatment with a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If), comprising the steps of: - Preparing a tumor cell-containing sample from a patient; determining whether the KRAS gene in a sample containing the patient's tumor cells encodes a wild-type (glycine at position 12) or mutant (cysteine, aspartic acid, valine, alanine or aginine at position 12, aspartic acid at position 13, amplified and / or overexpressed) KRAS protein; and Based on this, the formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) A method is provided that includes:

[0114] The method may or may not include the step of isolating the actual patient sample.

[0115] According to another aspect, a compound represented by the formula (I), (I * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0116] According to another aspect, there is provided a compound represented by formula (I), (I) for use in treating a cancer having tumor cells harboring an amplification of a G12C mutant, a G12D mutant, a G12V mutant, a G12A mutant, a G13D mutant or a G12R mutant KRAS gene, or a KRAS wild type. *The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0117] According to another aspect, a compound represented by the formula (I), (I) for use in treating a cancer having tumor cells harboring an amplification of a G12C mutant, a G12D mutant, a G12V mutant or a G13D mutant KRAS gene, or a KRAS wild type. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0118] According to another aspect, a compound according to formula (I), (I * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0119] According to another aspect, a compound according to formula (I), (I * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0120] According to another aspect, a compound according to formula (I), (I * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0121] According to another aspect, there is provided a compound according to formula (I), (I) for use in treating cancer having tumor cells harboring wild-type amplified KRAS or overexpressed KRAS. * The present invention provides a compound represented by the formula: (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof.

[0122] According to another embodiment, an effective amount of a compound of formula (I), (I * The present invention provides a method for treating a cancer having tumor cells harboring an amplification of a G12C, G12D, G12V, G12A, G13D or G12R mutant KRAS gene, or a wild-type KRAS gene, comprising administering to a human a compound of the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0123] According to another embodiment, an effective amount of a compound of formula (I), (I * The present invention provides a method for treating a cancer having tumor cells harboring an amplification of a G12C mutant, a G12D mutant, a G12V mutant, a G12A mutant or a G12R mutant KRAS gene, or a wild-type KRAS gene, comprising administering a compound of the formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutical acceptable salt thereof.

[0124] Determining whether a tumor or cancer contains a G12C KRAS mutation can be performed by evaluating the nucleotide sequence encoding the KRAS protein, by evaluating the amino acid sequence of the KRAS protein, or by evaluating the characteristics of a putative KRAS mutant protein. The sequence of wild-type human KRAS is known in the art. Methods for detecting mutations in KRAS nucleotide sequences are known to those skilled in the art. These methods include, but are not limited to, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay, polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) assay, real-time PCR assay, PCR sequencing, mutant allele-specific PCR amplification (MASA) assay, direct sequencing, primer extension reaction, electrophoresis, oligonucleotide ligation assay, hybridization assay, TaqMan assay, SNP genotyping assay, high-resolution melting assay, and microarray analysis. In some embodiments, samples are evaluated for G12C KRAS mutations by real-time PCR. In real-time PCR, a fluorescent probe specific for KRAS G12C mutation is used. If the mutation is present, the probe binds and fluorescence is detected. In some embodiments, the KRAS G12C mutation is identified using a direct sequencing method of a specific region (e.g., exon 2 and / or exon 3) in the KRAS gene. This technique identifies all possible mutations in the sequenced region. Methods for detecting mutations in KRAS protein are known to those skilled in the art. These methods include, but are not limited to, detection of KRAS mutants using binding substances (e.g., antibodies) specific for mutant proteins, protein electrophoresis, Western blotting, and direct peptide sequencing.

[0125] The method for determining whether a tumor or cancer contains a G12C KRAS mutation can use a wide variety of samples. In some embodiments, the sample is taken from a subject with a tumor or cancer. In some embodiments, the sample is a fresh tumor / cancer sample. In some embodiments, the sample is a frozen tumor / cancer sample. In some embodiments, the sample is a formalin-fixed paraffin-embedded sample. In some embodiments, the sample is processed into a cell lysate. In some embodiments, the sample is processed into DNA or RNA. In some embodiments, the sample is a liquid biopsy and tests are performed on a blood sample to look for cancer cells from the tumor circulating in the blood or fragments of DNA from tumor cells in the blood.

[0126] Similarly, it can be determined whether the tumor or cancer contains KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and KRAS G12R mutations, or is KRAS wild type, preferably amplified.

[0127] Preferably, the compound of formula (I), (I * The disease / condition / cancer / tumor / cancer cell to be treated / prevented according to the methods and uses as defined and disclosed herein (above and below) with a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof is selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, appendix cancer, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, esophageal cancer, gastroesophageal cancer, chronic lymphocytic leukemia, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer and sarcoma.

[0128] Preferably, the compound of formula (I), (I *The disease / condition / cancer / tumor / cancer cell to be treated / prevented according to the methods and uses as defined and disclosed herein (above and below) using a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof is selected from the group consisting of pancreatic cancer, lung cancer, ovarian cancer, colorectal cancer (CRC), gastric cancer, gastroesophageal junction cancer (GEJC) and esophageal cancer.

[0129] In another embodiment, the compound of formula (I), (I * The disease / condition / cancer / tumor / cancer cell to be treated / prevented according to the methods and uses as defined and disclosed herein (above and below) using a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof is selected from the group consisting of pancreatic cancer (preferably pancreatic ductal adenocarcinoma (PDAC)), lung cancer (preferably non-small cell lung cancer (NSCLC)), gastric cancer, cholangiocarcinoma and colon cancer (preferably colon adenocarcinoma). Preferably, said pancreatic cancer, lung cancer, cholangiocarcinoma, colon cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) or colon adenocarcinoma comprises a KRAS mutation, in particular a KRAS G12D or KRAS G12V mutation. Preferably (alternatively or in combination with the previous preferred embodiments), said non-small cell lung cancer (NSCLC) comprises a mutation (in particular a loss-of-function mutation) in the NF1 gene.

[0130] In another embodiment, the compound of formula (I), (I *The disease / condition / cancer / tumor / cancer cell to be treated / prevented according to the methods and uses as defined and disclosed herein (above and below) with a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof is gastric cancer, ovarian cancer or esophageal cancer, said gastric cancer or esophageal cancer preferably selected from the group consisting of gastric adenocarcinoma (GAC), esophageal adenocarcinoma (EAC) and gastroesophageal junction cancer (GEJC). Preferably, said gastric cancer, ovarian cancer, esophageal cancer, gastric adenocarcinoma (GAC), esophageal adenocarcinoma (EAC) or gastroesophageal junction cancer (GEJC) comprises a KRAS mutation or a wild-type amplified KRAS.

[0131] Particularly preferred are compounds represented by formula (I), (I * The cancers to be treated / prevented according to the methods and uses as defined and disclosed herein (above and below) using a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof are selected from the group consisting of: - lung adenocarcinoma (preferably non-small cell lung cancer (NSCLC)) carrying a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation), a KRAS mutation at position 13 (preferably G13D) or an amplification of KRAS wild type; colon adenocarcinoma carrying a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation), a KRAS mutation at position 13 (preferably G13D) or an amplification of KRAS wild type; Pancreatic adenocarcinoma (preferably pancreatic ductal adenocarcinoma (PDAC)) carrying a RAS mutation at position 12 (preferably KRAS, preferably a G12C, G12D, G12V, G12A, G12R mutation), a RAS mutation at position 13 (preferably G13D) or an amplification of KRAS wild type.

[0132] Preferably, "cancer" as used herein (above or below) includes drug-resistant cancers and cancers that have failed first, second or more monotherapy or combination therapy with one or more anticancer drugs. In particular, "cancer" (and any embodiment thereof) refers to any cancer (especially the cancer types defined hereinabove and below) that is resistant to treatment with a KRAS G12C inhibitor.

[0133] Various resistance mechanisms have already been reported. For example, the following papers describe resistance in patients after treatment with KRAS G12C inhibitors: (i) Awad MM, Liu S, Rybkin, II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med 2021;384:2382-93, and (ii) Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski Et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov 2021;11:1913-22.

[0134] In another embodiment, the compound of formula (I), (I *The diseases / conditions / cancers / tumors / cancer cells to be treated / prevented according to the methods and uses as defined and disclosed herein (above and below) with a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof are RAS diseases, preferably selected from the group consisting of Neurofibromatosis Type 1 (NF1), Noonan Syndrome (NS), Noonan Syndrome with Multiple Lentigines (NSML) (also known as LEOPARD syndrome), Capillary Malformation-Arteriovenous Malformation Syndrome (CM-AVM), Costello Syndrome (CS), Cardio-Facio-Cutaneous Syndrome (CFC), Regius Syndrome (also known as NF1-like syndrome) and Hereditary Gingival Fibromatosis.

[0135] In addition, the following cancers, tumors and other proliferative diseases are treated with the compound represented by formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutical acceptable salt thereof. Preferably, the methods of treatment, methods, uses, compounds to be used and pharmaceutical compositions to be used as disclosed herein (above and below) are applied in the treatment of diseases / conditions / cancers / tumors (i.e., respective cells) that carry a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation) or a KRAS wild-type amplification, or that have been identified as carrying a KRAS mutation at position 12 (preferably G12C, G12D, G12V, G12A, G12R mutation) or a KRAS wild-type amplification, as described and / or referenced herein: Cancers / tumours / carcinomas of the head and neck: for example, tumours / carcinomas of the nasal cavity, paranasal sinuses, nasopharynx, oral cavity (including lips, gums, alveolar ridge, retromolar triangle, floor of mouth, tongue, hard palate, buccal mucosa), oropharynx (including base of tongue, tonsils, tonsillar pillars, soft palate, tonsillar fossa, pharyngeal wall), middle ear, larynx (including supraglottis, glottis, subglottis, vocal cords), hypopharynx, salivary glands (including minor salivary glands); Lung cancer / tumour / carcinoma: e.g. non-small cell lung cancer (NSCLC) (squamous cell carcinoma, spindle cell carcinoma, adenocarcinoma, large cell carcinoma, clear cell carcinoma, bronchoalveolar carcinoma), small cell lung cancer (SCLC) (oat cell carcinoma, intermediate cell carcinoma, mixed oat cell carcinoma); Mediastinal neoplasms: for example, neurogenic tumors (including neurofibroma, schwannoma, malignant schwannoma, neurosarcoma, ganglioneuroblastoma, ganglioneuroma, neuroblastoma, pheochromocytoma, paraganglioma), germ cell tumors (including seminoma, teratoma, nonseminoma), thymic tumors (including thymoma, thymolipoma, thymic carcinoma, thymic carcinoid), mesenchymal tumors (including fibroma, fibrosarcoma, lipoma, liposarcoma, myxoma, mesothelioma, leiomyoma, leiomyosarcoma, rhabdomyosarcoma, xanthogranuloma, mesenchymoma, hemangioma, hemangioendothelioma, hemangiopericytoma, lymphangiomoma, lymphangioleiomyoma); Cancers / tumors / carcinomas of the gastrointestinal (GI) tract: e.g. tumors / carcinomas / cancer of the following: esophagus, stomach (gastric cancer), cancer of the esophagogastric junction, pancreas, liver and biliary system (including hepatocellular carcinoma (HCC), e.g. childhood HCC, fibrolamellar HCC, mixed HCC, spindle cell HCC, clear cell HCC, giant cell HCC, carcinosarcoma HCC, sclerosing HCC; hepatoblastoma; cholangiocarcinoma; cholangiocarcinoma; hepatic cystadenocarcinoma; angiosarcoma, hemangioendothelioma, leiomyosarcoma, malignant schwannoma, fibrosarcoma, Klatzkin tumor), gallbladder, extrahepatic bile duct, small intestine (duodenal , jejunum, ileum), large intestine (including cecum, colon, rectum, anus; colorectal cancer, gastrointestinal stromal tumor (GIST)), genitourinary system (kidney, e.g., including renal pelvis, renal cell carcinoma (RCC), nephroblastoma (Wilms' tumor), adrenal gland, Grabitz tumor; ureter; bladder, e.g., urachal carcinoma, urothelial carcinoma; urethra, e.g., distal, bulbomembranous, prostatic; prostate (androgen-dependent, androgen-independent, castration-resistant, hormone-independent, hormone-refractory), penis), stomach cancer; Cancer / tumor / carcinoma of the testis: e.g. seminoma, non-seminoma, Gynecologic cancer / tumor / carcinoma: for example, tumor / carcinoma / cancer of the ovary, fallopian tube, peritoneum, cervix, vulva, vagina, uterine body (including endometrium, fundus); Cancers / tumors / carcinomas of the breast: e.g., breast cancer (infiltrating ductal, colloid, lobular infiltrating, tubular, adenoid cystic, papillary, medullary, mucinous), hormone receptor positive breast cancer (estrogen receptor positive breast cancer, progesterone receptor positive breast cancer), Her2 positive breast cancer, triple negative breast cancer, Paget's disease of the breast; Cancers / tumors / carcinomas of the endocrine system: for example, tumors / tumors of the following: endocrine glands, thyroid (thyroid carcinoma / tumors; papillary, follicular, anaplastic, medullary), parathyroid (parathyroid carcinoma / tumors), adrenal cortex (adrenal cortical carcinoma / tumors), pituitary (including prolactinoma, craniopharyngioma), thymus, adrenal gland, pineal gland, carotid body, islet cell tumors, paraganglia, pancreatic endocrine tumors (PET; non-functioning PET, PPoma, gastrinoma, insulinoma, VIPoma, glucagonoma, somatostatinoma, GRFoma, ACTHoma), carcinoid tumors; Sarcomas of soft tissues: e.g., fibrosarcoma, fibrous histiocytoma, liposarcoma, leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, lymphangiosarcoma, Kaposi's sarcoma, glomus tumor, hemangiopericytoma, synovial sarcoma, giant cell tumor of tendon sheath, solitary fibrous tumor of pleura and peritoneum, diffuse mesothelioma, malignant peripheral nerve sheath tumor (MPNST), granular cell tumor, clear cell sarcoma, melanocytic schwannoma, plexosarcoma, neuroblastoma, ganglioneuroblastoma, neuroepithelioma, extraskeletal Ewing's sarcoma, paraganglioma, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, mesenchymoma, alveolar soft part sarcoma, epithelioid sarcoma, extrarenal rhabdoid tumor, desmoplastic small cell tumor; Sarcomas of bone: e.g., myeloma, reticulum cell sarcoma, chondrosarcoma (including central, peripheral, clear cell, and mesenchymal chondrosarcoma), osteosarcoma (including parosteal, periosteal, superficial high-grade, small cell, radiation-induced osteosarcoma, and Paget's sarcoma), Ewing's tumor, malignant giant cell tumor, adamantinoma, (fibrous) histiocytoma, fibrosarcoma, chordoma, small round cell sarcoma, hemangioendothelioma, hemangiopericytoma, osteochondroma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, and chondroblastoma; Mesothelioma: e.g. pleural mesothelioma, peritoneal mesothelioma; Cancers of the skin: e.g. basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, melanoma (including cutaneous, superficial spreading, lentigo maligna, acral lentigo, nodular, and intraocular melanoma), actinic keratosis, and eyelid cancer; Neoplasms of the central nervous system and brain: e.g., astrocytomas (cerebral, cerebellar, diffuse, fibrillary, anaplastic, pilocytic, protoplasmic, gemistocytary), glioblastomas, gliomas, oligodendrogliomas, oligoastrocytomas, ependymoblastomas, choroid plexus tumors, medulloblastomas, meningiomas, schwannomas, hemangioblastomas, hemangiomas, hemangiopericytomas, neuromas, ganglioneuromas, neuroblastomas, retinoblastomas, schwannomas (e.g., auditory), spinal axis tumors; Lymphomas and leukemias: for example, B-cell non-Hodgkin's lymphoma (NHL) (including small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma (BL)), T-cell non-Hodgkin's lymphoma (including anaplastic large cell lymphoma (ALCL), adult T-cell leukemia / lymphoma (including ATLL), cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL)), lymphoblastic T-cell lymphoma (T-LBL), adult T-cell lymphoma, lymphoblastic B-cell lymphoma (B-LBL), immunocytoma, chronic B-cell lymphocytic leukemia (B-CLL), chronic T-cell lymphocytic leukemia (T-CLL), B-cell small lymphocytic lymphoma (B-SLL), cutaneous T Cellular lymphoma (CTLC), primary central nervous system lymphoma (PCNSL), immunoblastoma, Hodgkin's disease (HD) (including nodular lymphocyte predominant HD (NLPHD), nodular sclerosing HD (NSHD), mixed cellularity HD (MCHD), lymphocyte-rich classical HD, lymphopenic HD (LDHD)), large granular lymphocytic leukemia (LGL), chronic myeloid leukemia (CML), acute myeloid leukemia (ACML), / myelocytic leukemia (AML), acute lymphocytic / lymphoblastic leukemia (ALL), acute promyelocytic leukemia (APL), chronic lymphocytic / lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia, chronic myelogenous / myeloid leukemia (CML), myeloma, plasmacytoma, multiple myeloma (MM), plasmacytoma, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML); carcinoma of unknown primary site (CUP);

[0136] All cancers / tumors / carcinomas mentioned above, characterized by their specific location / origin within the body, are meant to include both the primary tumor and the metastatic tumors derived therefrom.

[0137] All the above mentioned cancers / tumors / carcinomas can be further differentiated by their histopathological classification: Epithelial carcinomas, e.g., squamous cell carcinoma (SCC) (carcinoma in situ, superficial invasive, warty carcinoma, pseudosarcoma, undifferentiated, transitional cell, lymphoepithelial), adenocarcinoma (AC) (well-differentiated, mucinous, papillary, pleomorphic giant cell, tubular, small cell, signet ring cell, spindle cell, clear cell, oat cell, colloid, adenosquamous, mucoepidermoid, adenoid cystic), mucinous cystadenocarcinoma, acinic cell carcinoma, large cell carcinoma, small cell carcinoma, neuroendocrine tumors (small cell carcinoma, paraganglioma, carcinoid); oncocytic carcinoma; Non-epithelial carcinomas, such as sarcomas (fibrosarcoma, chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, angiosarcoma, giant cell sarcoma, lymphosarcoma, fibrous histiocytoma, liposarcoma, angiosarcoma, lymphangiosarcoma, neurofibrosarcoma), lymphoma, melanoma, germ cell tumors, hematopoietic tumors, mixed and undifferentiated carcinomas;

[0138] The compounds of the invention may be used in treatment regimens as first line treatment, second line treatment, or any further line of treatment.

[0139] The compounds of the invention may be used for the prevention, short-term or long-term treatment of the above mentioned diseases / conditions / cancers / tumors, optionally also in combination with radiation therapy and / or surgery.

[0140] The methods of treatment, methods, uses and compounds of use as disclosed herein (above and below) are of formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, and * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof (respectively represented by formula (I), (I *The present invention may be practiced with any pharmaceutical composition or kit comprising any individual embodiment or inclusive subset of the compounds represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If).

[0141] Combination treatment Formula (I), (I * The compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or pharma- ceutically acceptable salts thereof, and pharmaceutical compositions containing such compounds or salts, may also be co-administered with other pharmacologically active substances, such as other anti-neoplastic compounds (e.g., chemotherapy), or may be used as an adjuvant before or after surgery in conjunction with other treatments, such as radiation or surgical intervention. Preferably, the co-administered pharmacologically active substance is an anti-neoplastic compound.

[0142] Thus, in a further aspect, the present invention relates to a compound of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, administered before, after or together with one or more other pharmacologically active substances.

[0143] In a further aspect, the present invention relates to a compound of formula (I), (I * or a pharma- ceutically acceptable salt thereof, wherein said compound or a pharma- ceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.

[0144] In a further aspect, the present invention relates to a compound of formula (I), (I *The present invention relates to the use of a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein said compound is administered before, after or together with one or more other pharmacologically active substances.

[0145] In a further aspect, the present invention relates to a method (e.g. a method for the treatment and / or prevention) as defined herein above, comprising administering to a subject a compound of formula (I), (I * The present invention relates to a method of administering a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, before, after or together with a therapeutically effective amount of one or more other pharmacologically active substances.

[0146] In a further aspect, the present invention relates to a method (e.g. a method for the treatment and / or prevention) as defined herein above, comprising administering to a subject a compound of formula (I), (I * The present invention relates to a method of administering a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more other pharmacologically active substances.

[0147] In a further aspect, the present invention provides a method for providing a therapeutically effective amount of a compound represented by formula (I), (I * A method for the treatment and / or prevention of cancer, comprising administering a compound represented by formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof and one or more other pharmacologically active substances in a therapeutically effective amount. * The present invention relates to a method of administering a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, simultaneously, concomitantly, sequentially, consecutively, alternatingly or separately with one or more other pharmacologically active substances.

[0148] In a further aspect, the present invention relates to a method for the treatment and / or prevention of cancer comprising administering to a patient in need thereof a therapeutically effective amount of an inhibitor of KRAS mutated at residue 12 or 13, such as an inhibitor of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and / or KRAS G12R, preferably a KRAS G12C, KRAS G12D or selective KRAS G12D inhibitor or a pharma- ceutically acceptable salt thereof and a therapeutically effective amount of one or more other pharmacologically active substances, wherein the inhibitor or a pharma- ceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.

[0149] In a further aspect, the present invention relates to a method for the treatment and / or prevention of cancer comprising administering to a patient in need thereof a therapeutically effective amount of an inhibitor of amplified or overexpressed wild type KRAS, or a pharma- ceutically acceptable salt thereof, and a therapeutically effective amount of one or more other pharmacologically active substances, wherein the inhibitor or a pharma- ceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.

[0150] In a further aspect, the present invention relates to a compound of formula (I), (I * or a pharma- ceutically acceptable salt thereof, which is administered simultaneously, in parallel, sequentially, consecutively, alternatingly or separately with one or more other pharmacologically active substances, * The present invention relates to a compound represented by formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof.

[0151] In a further aspect, the present invention relates to an inhibitor of KRAS mutated at residue 12 or 13, such as an inhibitor of KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12A, KRAS G13D and / or KRAS G12R, preferably a KRAS G12C, KRAS G12D or selective KRAS G12D inhibitor or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of cancer, which is administered in combination with one or more other pharmacologically active substances.

[0152] In a further aspect, the present invention relates to an inhibitor of amplified or overexpressed wild type KRAS, or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of cancer, wherein the inhibitor or a pharma- ceutically acceptable salt thereof is administered in combination with one or more other pharmacologically active substances.

[0153] In a further aspect, the present invention provides a method for producing a composition comprising the steps of: Formula (I), (I * a first pharmaceutical composition or dosage form comprising a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, and optionally one or more pharma- ceutically acceptable excipients; and A second pharmaceutical composition or dosage form comprising another pharmacologically active substance and optionally one or more pharma- ceutically acceptable excipients. A kit for use in the treatment and / or prevention of cancer, comprising The present invention relates to a kit, wherein the first pharmaceutical composition is intended to be administered simultaneously, concurrently, sequentially, consecutively, alternatingly or separately from the second and / or additional pharmaceutical compositions or dosage forms.

[0154] In one embodiment, such a kit for said use comprises a third pharmaceutical composition or dosage form, which further comprises another pharmacologically active substance and optionally one or more pharma- ceutically acceptable excipients.

[0155] In a further embodiment of the invention, the components (i.e. combination partners) of the combinations, kits, uses, methods and compounds of use according to the invention (including all embodiments) are administered simultaneously.

[0156] In a further embodiment of the invention, the components (i.e. combination partners) of the combinations, kits, uses, methods and compounds of use according to the invention (including all embodiments) are administered concurrently.

[0157] In a further embodiment of the invention, the components (i.e. combination partners) of the combinations, kits, uses, methods and compounds of use according to the invention (including all embodiments) are administered sequentially.

[0158] In a further embodiment of the invention, the components (i.e. combination partners) of the combinations, kits, uses, methods and compounds of use according to the invention (including all embodiments) are administered sequentially.

[0159] In a further embodiment of the invention, the components (i.e. combination partners) of the combinations, kits, uses, methods and compounds of use according to the invention (including all embodiments) are administered alternately.

[0160] In a further embodiment of the invention, the components (i.e. combination partners) of the combinations, kits, uses, methods and compounds of use according to the invention (including all embodiments) are administered separately.

[0161] Formula (I), (I *The pharmacologically active substance used in conjunction / combination with a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof (including any individual embodiment or inclusive subset of the compounds), or in the medical uses, uses as defined herein (above and below), methods of treatment and / or prophylaxis, pharmaceutical compositions, may be selected from any one or more of the following (preferably there are one or two additional pharmacologically active substances used in all these embodiments):

[0162] 1. Inhibitors of EGFR and / or ErbB2 (HER2) and / or ErbB3 (HER3) and / or ErbB4 (HER4) or any mutants thereof a. Irreversible inhibitors: e.g., afatinib, dacomitinib, canertinib, neratinib, avitinib, poziotinib, AV 412, PF-6274484, HKI 357, olmutinib, osimertinib, almonertinib, nazartinib, lazertinib, pelitinib; b. Reversible inhibitors: e.g., erlotinib, gefitinib, icotinib, sapitinib, lapatinib, varlitinib, vandetanib, TAK-285, AEE788, BMS599626 / AC-480, GW 583340; c. Anti-EGFR antibodies: e.g., necitumumab, panitumumab, cetuximab, amivantamab; d. Anti-HER2 antibodies: for example, pertuzumab, trastuzumab, trastuzumab-emtansine; e. Inhibitors of mutant EGFR; f. Inhibitors of HER2 with exon 20 mutations; g. The preferred irreversible inhibitor is afatinib; h. A preferred anti-EGFR antibody is cetuximab.

[0163] 2. Inhibitors of MEK and / or its mutants For example, trametinib, cobimetinib, binimetinib, selumetinib, refametinib; b. Preferred is trametinib c. MEK inhibitors such as those disclosed in WO 2013 / 136249; d. MEK inhibitors as disclosed in WO 2013 / 136254.

[0164] 3. Inhibitors of SOS1 and / or any mutants thereof (i.e. compounds that modulate / inhibit the GEF function of SOS1, for example by binding to SOS1 and blocking the protein-protein interaction between SOS1 and (mutant) Ras proteins, such as KRAS). For example, BAY-293; b. SOS1 inhibitors as disclosed in WO 2018 / 115380; c. SOS1 inhibitors as disclosed in WO 2019 / 122129; d. SOS1 inhibitors such as those disclosed in WO 2020 / 180768, WO 2020 / 180770, WO 2018 / 172250 and WO 2019 / 201848.

[0165] 4. Oncolytic viruses

[0166] 5. RAS Vaccine For example, TG02 (Targovax)

[0167] 6. Cell Cycle Inhibitors For example, an inhibitor of CDK4 / 6 and / or any mutant thereof i. For example, palbociclib, ribociclib, abemaciclib, trilaciclib, PF-06873600; ii. Preferred are palbociclib and abemaciclib; iii. Most preferred is abemaciclib. b. For example, vinca alkaloids i. For example, vinorelbine c. For example, an inhibitor of Aurora kinase and / or any mutant thereof i. For example, alisertib, barasertib.

[0168] 7. Inhibitors of PTK2 (=FAK) and / or any mutants thereof For example, TAE226, BI 853520.

[0169] 8. Inhibitors of SHP2 and / or any mutant thereof a.For example, SHP099, TNO155, RMC-4550, RMC-4630, IACS-13909.

[0170] 9. Inhibitors of PI3 kinase (=PI3K) and / or any mutant thereof For example, an inhibitor of PI3K alpha and / or any mutant thereof i. For example, alpelisib, ceravelisib, GDC-0077, HH-CYH33, AMG 511, buparlisib, dactolisib, pictilisib, taselisib.

[0171] 10. Inhibitors of FGFR1 and / or FGFR2 and / or FGFR3 and / or any mutants thereof For example, ponatinib, infigratinib, nintedanib.

[0172] 11. Inhibitors of AXL and / or any of its mutants

[0173] 12. Taxanes For example, paclitaxel, nab-paclitaxel, docetaxel; b. Preferred is paclitaxel.

[0174] 13.Platinum-containing compounds For example, cisplatin, carboplatin, oxaliplatin b. Preferred is oxaliplatin.

[0175] 14. Antimetabolites For example, 5-fluorouracil, capecitabine, floxuridine, cytarabine, gemcitabine, pemetrexed, trifluridine and tipiracil (=TAS102); b. Preferred is 5-fluorouracil.

[0176] 15. Immunotherapy For example, immune checkpoint inhibitors i. For example, anti-CTLA4 mAb, anti-PD1 mAb, anti-PD-L1 mAb, anti-PD-L2 mAb, anti-LAG3 mAb, anti-TIM3 mAb; ii. Preferred is an anti-PD1 mAb; iii. For example, ipilimumab, nivolumab, pembrolizumab, tislelizumab, atezolizumab, avelumab, durvalumab, pidilizumab, PDR-001 (= spartalizumab), AMG-404, ezabenlimab; iv. Preferred are nivolumab, pembrolizumab, ezabenlimab and PDR-001 (= spartalizumab); v. Most preferred are ezabenlimab, pembrolizumab and nivolumab.

[0177] 16. Topoisomerase inhibitors a. For example, irinotecan, liposomal irinotecan (nal-IRI), topotecan, etoposide; b. Most preferred are irinotecan and liposomal irinotecan (nal-IRI).

[0178] 17. Inhibitors of A-Raf and / or B-Raf and / or C-Raf and / or any mutants thereof For example, encorafenib, dabrafenib, vemurafenib, PLX-8394, RAF-709 (= Example 131 in WO 2014 / 151616), LXH254, sorafenib, LY-3009120 (= Example 1 in WO 2013 / 134243), lifirafenib, TAK-632, agerafenib, CCT196969, RO5126766, RAF265.

[0179] 18. mTOR inhibitors For example, rapamycin, temsirolimus, everolimus, ridaforolimus, zotarolimus, sapanisertib, Torin 1, dactolisib, GDC-0349, VS-5584, vistusertib, AZD8055.

[0180] 19. Epigenetic Modulators For example, BET inhibitors i. For example, JQ-1, GSK 525762, OTX-015, CPI-0610, TEN-010, OTX-015, PLX51107, ABBV-075, ABBV-744, BMS986158, TGI-1601, CC-90010, AZD5153, I-BET151, BI 894999;

[0181] 20. Inhibitors of IGF1 / 2 and / or IGF1-R and / or any mutants thereof a. For example, xentuzumab (antibody 60833 in WO 2010 / 066868), MEDI-573 (=ducigitumab), linsitinib.

[0182] 21. Inhibitors of Src family kinases and / or any mutants thereof For example, inhibitors of kinases of the SrcA subfamily and / or any mutants thereof, i.e. inhibitors of Src, Yes, Fyn, Fgr and / or any mutants thereof; b. For example, inhibitors of kinases of the SrcB subfamily and / or any mutants thereof, i.e. inhibitors of Lck, Hck, Blk, Lyn and / or any mutants thereof; c. For example, inhibitors of kinases of the Frk subfamily and / or any mutants thereof, i.e., inhibitors of Frk and / or any mutants thereof; d. For example, dasatinib, ponatinib, bosutinib, vandetanib, KX-01, saracatinib, KX2-391, SU 6656, WH-4-023.

[0183] 22. Apoptosis Regulator a. For example, an MDM2 inhibitor, such as an inhibitor of the interaction between p53 (preferably functional p53, most preferably wt p53) and MDM2 and / or any mutant thereof; i. For example, HDM-201, NVP-CGM097, RG-7112, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-115; ii. Preferred are HDM-201, RG-7388 and AMG-232; iii. MDM2 inhibitors as disclosed in WO 2015 / 155332; iv. MDM2 inhibitors as disclosed in WO 2016 / 001376; v. MDM2 inhibitors, such as those disclosed in WO 2016 / 026937; vi. MDM2 inhibitors as disclosed in WO 2017 / 060431; b. For example, PARP inhibitors; c. For example, MCL-1 inhibitors; i. For example, AZD-5991, AMG-176, AMG-397, S64315, S63845, A-1210477.

[0184] 23. Inhibitors of c-MET and / or any of its mutants For example, savolitinib, cabozantinib, foretinib; b.MET antibodies, e.g., emibetuzumab, amivantamab;

[0185] 24. Inhibitors of ERK and / or any mutant thereof For example, ulixertinib, LTT462;

[0186] 25. Inhibitors of farnesyltransferase and / or any mutant thereof For example, tipifarnib;

[0187] 26. Inhibitors of YAP1, WWTR1, TEAD1, TEAD2, TEAD3 and / or TEAD4 a. Reversible inhibitors of TEAD transcription factors (e.g., as disclosed in WO 2018 / 204532); b. Irreversible inhibitors of TEAD transcription factors (e.g., as disclosed in WO 2020 / 243423); c. Protein-protein interaction inhibitors of the YAP / TAZ::TEAD interaction (e.g., as disclosed in WO 2021 / 186324); d. Inhibitors of TEAD palmitoylation.

[0188] In a further embodiment of the (combination) uses and methods (e.g. methods for treatment and / or prevention) as described herein above, one other pharmacologically active substance is a compound of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein said other pharmacologically active substance is: SOS1 inhibitors; or MEK inhibitors; or trametinib, or anti-PD-1 antibodies; or Ezabenlimab; or Cetuximab; or afatinib; or Standard of care (SoC) for a given indication; or PI3 kinase inhibitors; or Inhibitors of TEAD palmitoylation; or · YAP / TAZ::TEAD inhibitors.

[0189] In a further embodiment of the (combination) uses and methods (e.g. methods for treatment and / or prevention) as described herein above, one other pharmacologically active substance is a compound of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein the other pharmacologically active agent is: SOS1 inhibitors; or MEK inhibitors; or trametinib; or anti-PD-1 antibodies; or Ezabenlimab; or Cetuximab; or afatinib; or Standard of care (SoC) for a given indication; or PI3 kinase inhibitors; or Inhibitors of TEAD palmitoylation; or · YAP / TAZ::TEAD inhibitors.

[0190] In a further embodiment of the (combined) uses and methods (e.g. methods for treatment and / or prevention) as described herein above, two other pharmacologically active substances are selected from the group consisting of the compounds of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein the other two pharmacologically active substances are: MEK inhibitors and SOS1 inhibitors; or trametinib and an SOS1 inhibitor; or an anti-PD-1 antibody (preferably, ezabenlimab) and an anti-LAG-3 antibody; or an anti-PD-1 antibody (preferably, ezabenlimab) and an SOS1 inhibitor; or an inhibitor selected from the group consisting of a MEK inhibitor and an EGFR inhibitor and / or an ErbB2 (HER2) inhibitor and / or an inhibitor of any mutant thereof; or an inhibitor selected from the group consisting of an SOS1 inhibitor and an EGFR inhibitor and / or an ErbB2 (HER2) inhibitor and / or an inhibitor of any mutant thereof; or MEK inhibitors and afatinib; or MEK inhibitors and cetuximab; or trametinib and afatinib; or trametinib and cetuximab; or SOS1 inhibitors and afatinib; or SOS1 inhibitors and cetuximab; or SOS1 inhibitors and inhibitors of TEAD palmitoylation; or · SOS1 inhibitors and YAP / TAZ::TEAD inhibitors.

[0191] In a further embodiment of the (combined) uses and methods (e.g. methods for treatment and / or prevention) as described herein above, two other pharmacologically active substances are selected from the group consisting of the compounds of formula (I), (I * (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof, wherein the other two pharmacologically active substances are: MEK inhibitors and SOS1 inhibitors; or trametinib and an SOS1 inhibitor; or an anti-PD-1 antibody (preferably, ezabenlimab) and an anti-LAG-3 antibody; or an anti-PD-1 antibody (preferably, ezabenlimab) and an SOS1 inhibitor; or an inhibitor selected from the group consisting of a MEK inhibitor and an EGFR inhibitor and / or an ErbB2 (HER2) inhibitor and / or an inhibitor of any mutant thereof; or an inhibitor selected from the group consisting of an SOS1 inhibitor and an EGFR inhibitor and / or an ErbB2 (HER2) inhibitor and / or an inhibitor of any mutant thereof; or MEK inhibitors and afatinib; or MEK inhibitors and cetuximab; or trametinib and afatinib; or trametinib and cetuximab; or SOS1 inhibitors and afatinib; or SOS1 inhibitors and cetuximab; or SOS1 inhibitors and inhibitors of TEAD palmitoylation; or · SOS1 inhibitors and YAP / TAZ::TEAD inhibitors.

[0192] Formula (I), (I * ), (Ia), (Ib), (Ic), (Id), (Ie) or (If), or a pharma- ceutically acceptable salt thereof (formula (I), (I *Additional pharmacologically active substances which may also be used together / in combination with the compounds of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or in the medical uses, uses as defined herein (above and below), methods of treatment and / or prevention, pharmaceutical compositions, kits include hormones, hormone analogs and antihormones (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol, rifabutin ... acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g., anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g., goserelin acetate, luprolide), growth factors and / or their counterparts These include, but are not limited to, inhibitors of the corresponding receptors (such as growth factors, e.g., platelet derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), human epidermal growth factor (HER, e.g., HER2, HER3, HER4) and hepatocyte growth factor (HGF) and / or their corresponding receptors), such as, for example, (anti-)growth factor antibodies, (anti-)growth factor receptor antibodies and tyrosine kinase inhibitors, e.g., cetuximab, gefitinib, afatinib, nintedanib, imatinib, lapatinib, bosutinib, bevacizumab and trastuzumab; antimetabolites (e.g. folate antagonists, e.g. methotrexate, raltitrexed, pyrimidine analogues, e.g. 5-fluorouracil (5-FU), ribonucleoside and deoxyribonucleoside analogues, capecitabine and gemcitabine, purine and adenosine analogues, e.g. mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine (arabinose),C), fludarabine); antitumor antibiotics (e.g., anthracyclines such as doxorubicin, doxil (pegylated liposomal doxorubicin hydrochloride, myocet (non-pegylated liposomal doxorubicin), daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum derivatives (e.g., cisplatin, oxaliplatin, carboplatin); alkylating agents (e.g., estramustine, mechlorethamine, melphalan, chlorambucil, busulfan, dacarbazine, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas, such as carmustine and lomustine, thiotepa; antimitotic agents (e.g., vinca alkaloids, such as vinblastine, vindesine, vinorelbine and vincristine; and taxanes, such as paclitaxel, docetaxel); angiogenesis inhibitors (e.g., tasquinimod), tubulin inhibitors; DNA synthesis inhibitors, PARP inhibitors, topoisomerase inhibitors (e.g., epipodophyllotoxins, such as etoposide and etopophos, teniposide, amsacrine, topotecan, irinotecan, mitoxantrone), serine / threonine kinase inhibitors (e.g., PDK 1 inhibitors, Raf inhibitors, A-Raf inhibitors, B-Raf inhibitors, C-Raf inhibitors, mTOR inhibitors, mTORC1 / 2 inhibitors, PI3K inhibitors, PI3Kα inhibitors, dual mTOR / PI3K inhibitors, STK 33 inhibitors, AKT inhibitors, PLK1 inhibitors, inhibitors of CDKs, Aurora kinase inhibitors), tyrosine kinase inhibitors (e.g., PTK2 / FAK inhibitors), protein-protein interaction inhibitors (e.g., IAP inhibitors / SMAC mimetics, Mcl-1, MDM2 / MDMX), MEK inhibitors, ERK inhibitors, FLT3 inhibitors, BRD4 inhibitors, IGF-1R inhibitors, TRAILR2 agonists, Bcl-xL inhibitors, Bcl-2 inhibitors (e.g., venetoclax), Bcl-2 / Bcl-xL inhibitors, ErbB receptor inhibitors, BCR-ABL inhibitors, ABL inhibitors, Src inhibitors, rapamycin analogues (e.g., everolimus, temsirolimus, ridaforolimus, sirolimus), androgen synthesis inhibitors, androgen receptor inhibitors, DNMT inhibitors, HDAC inhibitors, ANG1 / 2 inhibitors, CYP17 inhibitors, radiopharmaceuticals, proteasome inhibitors (e.g., carfilzomib), immunotherapeutic agents, e.g. , immune checkpoint inhibitors (e.g., CTLA4, PD1, PD-L1, PD-L2, LAG3, and TIM3 binding molecules / immunoglobulins, such as ipilimumab, nivolumab, pembrolizumab, etc.), ADCC (antibody-dependent cell-mediated cytotoxicity) enhancers (e.g., anti-CD33 antibodies, anti-CD37 antibodies, anti-CD20 antibodies), t-cell engagers (e.g., bispecific T-cell engagers (BiTEs®), such as CD3×BCMA, CD3×CD33, CD3×CD19, PSMA×CD3), tumor vaccines, immunomodulators, such as STING agonists, and various chemotherapeutic agents, such as amifostine, anagrelide, clodronate, filgrastin, interferon, interferon alpha, leucovorin, procarbazine, levamisole, mesna, mitotane, pamidronate, and porfimer.

[0193] It is to be understood that the combinations, compositions, kits, methods, uses, pharmaceutical compositions or compounds of use according to the present invention may contemplate simultaneous, concurrent, sequential, consecutive, alternating or separate administration of the active ingredients or components. *The compound represented by formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof and one or more other pharmacologically active substances may be administered in a dependent or independent formulation, for example, a compound represented by formula (I), (I * It will be appreciated that a compound of formula (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof and one or more other pharmacologically active substances may be administered as part of the same pharmaceutical composition / dosage form or, preferably, may be administered in separate pharmaceutical compositions / dosage forms.

[0194] In this context, "combination" or "combined" includes, but is not limited to, within the meaning of the present invention, products resulting from mixing or combining two or more active ingredients, including both fixed and non-fixed (e.g., free) combinations (including kits) and uses, such as simultaneous, parallel, sequential, consecutive, alternating or separate use of components or ingredients. The term "fixed combination" means that the active ingredients are administered to a patient simultaneously in the form of a single entity or dosage. The term "non-fixed combination" means that the active ingredients are administered to a patient as separate entities simultaneously, in parallel or sequentially without specific time limitations, such administration providing a therapeutically effective level of the compound in the patient's body.

[0195] Formula (I), (I * The administration of a compound of formula (I), (Ia), (Ib), (Ic), (Id), (Ie) or (If) or a pharma- ceutically acceptable salt thereof and one or more other pharmacologically active substances may be carried out by co-administration of the active components or ingredients, for example by administering them simultaneously or in parallel in one single or two or more separate formulations or dosage forms. Alternatively, the compounds of formula (I), (I *)、(Ia)、(Ib)、(Ic)、(Id)、(Ie) or (If), or a pharmaceutically acceptable salt thereof, and one or more other pharmacologically active substances can be administered by sequentially or alternately administering the active components or ingredients, for example, in two or more separate formulations or dosage forms.

[0196] For example, co-administration includes administration at substantially the same time. This dosage form may also be referred to as "combined" administration. Parallel administration includes administering the active agents within the same general period, for example, on the same day, but not necessarily at the same time. Alternate administration involves administering one agent for a period, for example, over several days or a week, followed by administering another agent for a subsequent period, for example, over several days or a week, and then repeating this pattern for one or more cycles. Sequential or continuous administration involves administering one agent in one or more doses over a first period (e.g., over several days or a week), followed by administering another agent in one or more doses over a second and / or further period (e.g., over several days or a week). Also, overlapping schedules may be used, which includes administering the active agents on different days over the treatment period, but not necessarily following a regular order. Also, variations of these general guidelines may be used, for example, depending on the agents used and the condition of the subject.

[0197] Definitions Terms not specifically defined herein should be given the meanings ascribed to them by those of ordinary skill in the art in light of the present disclosure and the context. However, as used herein, unless the contrary is specified, the following terms have the indicated meanings and the following conventions are observed:

[0198] Prefix C x-y [wherein x and y each represent a positive integer (x < y)] is used to indicate that the entire chain or ring structure or combination of chain and ring structures directly associated with the specification and reference may consist of carbon atoms having a maximum value of y and a minimum value of x.

[0199] References to the number of members in groups containing one or more heteroatoms (eg, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl) refer to the total number of atoms of all ring members or the total number of all ring members and carbon chain moieties.

[0200] References to the number of carbon atoms in groups consisting of a combination of carbon chain and carbon ring structures (e.g., cycloalkylalkyl, arylalkyl) refer to the total number of carbon atoms in all carbon ring members and the carbon chain portion. Of course, the ring structure has at least three members.

[0201] In general, for groups that contain two or more subgroups (e.g., heteroarylalkyl, heterocyclylalkyl, cycloalkylalkyl, arylalkyl), the last named subgroup is the point of attachment of the group, e.g., the substituent aryl-C 1-6 Alkyl is C 1-6 C means an aryl group bonded to an alkyl group. 1-6 The alkyl group is bonded to the nucleus or to a group to which the substituent is bonded.

[0202] For groups such as HO, H2N, (O)S, (O)2S, NC (cyano), HOOC, F3C, etc., one skilled in the art will recognize the point of attachment of the group to the molecule from the free valence of the group itself.

[0203] The expression "a compound of the present invention" and grammatical variations thereof refer to a compound of formula (I), (I * The compounds of the present invention include compounds of formula (I), (Ib), (Ic), (Id), (Ie) and (If), including all salts, aspects and preferred embodiments thereof as defined herein. * Any reference to compounds designated (Ia), (Ib), (Ic), (Id), (Ie) and (If) is intended to include a reference to each (sub-) aspect and embodiment.

[0204] Alkyldenotes a monovalent saturated hydrocarbon chain which may exist both in linear (unbranched) and branched form. If an alkyl is substituted, the substitutions may take place independently of one another, by mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms.

[0205] "C 1-5 The term "alkyl" includes, for example, HC-, HC-CH-, HC-CH-CH-, HC-CH(CH)-, HC-CH-CH-CH-, HC-CH(CH)-, HC-CH-CH-CH-, HC-CH(CH)-CH-, HC-C(CH)-, HC-CH-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-CH-CH-, HC-CH-C(CH)-, HC-C(CH)-CH-, HC-CH(CH)-CH-, HC-CH-CH-CH-, and HC-CH-CH(CHCH)-.

[0206] Further examples of alkyl are methyl (Me; -CH3), ethyl (Et; -CH2CH3), 1-propyl (n-propyl; n-Pr; -CH2CH2CH3), 2-propyl (i-Pr; iso-propyl; -CH(CH3)2), 1-butyl (n-butyl; n-Bu; -CH2CH2CH2CH3), 2-methyl-1-propyl (iso-butyl; i-Bu; -CH2CH(CH3)2), 2-butyl (sec-butyl; sec-Bu; -CH(CH3)CH2CH3), 2-methyl-2-propyl (tert-butyl; t-Bu; -C(CH3)3), 1-pentene (n-butyl; n-Bu; -CH2CH2CH2CH3), 2-methyl-2-propyl (tert-butyl; t-Bu; -C(CH3)3), 2-pentene (n-butyl; n-Bu; -CH2 ... ethyl (n-pentyl; -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 3-methyl-1-butyl (iso-pentyl; -CH2CH2CH(CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 2,2-dimethyl-1-propyl (neo-pentyl; -CH2C(CH3)3), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (n-hexyl;-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(C(CH3)2CH2CH2CH3), H3)CH2CH(CH3)2), 3-Methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-Methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-Dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-Dimethyl-2-butyl (-CH(CH3)C(CH3)3), 2,3-Dimethyl-1-butyl (-CH2CH (CH3)CH(CH3)CH3), 2,2-dimethyl-1-butyl (-CH2C(CH3)2CH2CH3), 3,3-dimethyl-1-butyl (-CH2CH2C(CH3)3), 2-methyl-1-pentyl (-CH2CH(CH3)CH2CH2CH3), 3-methyl-1-pentyl (-CH2CH2CH(CH3)CH2CH3), 1-heptyl (n-heptyl), 2-Methyl-1-hexyl, 3-Methyl-1-hexyl, 2,2-dimethyl-1-pentyl, 2,3-dimethyl-1-pentyl, 2,4-dimethyl-1-pentyl, 3,3-dimethyl-1-pentyl, 2,2,3-trimethyl-1-butyl, 3-ethyl-1-pentyl, 1-octyl (n-octyl), 1-nonyl (n-nonyl); 1-decyl (n-decyl), etc.;

[0207] The terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc., unless otherwise further defined, refer to saturated hydrocarbon groups having the corresponding number of carbon atoms and include all isomeric forms.

[0208] The above definition of alkyl also applies when alkyl is, for example, C x-y Alkylamino or C x-y This also applies when it is part of another (combined) group, such as alkyloxy.

[0209] AlkyleneThe term can also be derived from alkyl. Alkylene, unlike alkyl, is divalent and requires two binding partners. Formally, the second valency is generated by removing a hydrogen atom in an alkyl. Corresponding groups are, for example, -CH3 and -CH2-, -CH2CH3 and -CH2CH2- or >CHCH3.

[0210] "C 1-4 The term "alkylene" includes, for example, -(CH2)-, -(CH2-CH2)-, -(CH(CH3))-, -(CH2-CH2-CH2)-, -(C(CH3)2)-, -(CH(CH2CH3))-, -(CH(CH3)-CH2)-, -(CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH(CH3)-C H2-CH2)-, -(CH2-CH(CH3)-CH2)-, -(CH2-C(CH3)2)-, -(C(CH3)2-CH2)-, -(CH(CH3)-CH(CH3))-, -(CH2- CH(CH2CH3))-, -(CH(CH2CH3)-CH2)-, -(CH(CH2CH2CH3))-, -(CH(CH(CH3))2)- and -C(CH3)(CH2CH3)-.

[0211] Other examples of alkylene are methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1,1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, hexylene, and the like.

[0212] The generic terms propylene, butylene, pentylene, hexylene, etc., unless any further definition is intended to mean all the possible isomeric forms with the corresponding number of carbon atoms, i.e., propylene includes 1-methylethylene, butylene includes 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.

[0213] The above definition of alkylene also means that alkylene is, for example, HO-C x-y Alkyleneamino or H2N-C x-y This also applies when it is part of another (combined) group, such as alkyleneoxy.

[0214] Unlike alkyl, Alkenyl consists of at least two carbon atoms, where at least two adjacent carbon atoms are connected together by a CC double bond, and a carbon atom can only be part of one CC double bond. In an alkyl as defined herein above having at least two carbon atoms, when two hydrogen atoms on adjacent carbon atoms are formally removed and the free valences are saturated to form a second bond, the corresponding alkenyl is formed.

[0215] Examples of alkenyl are vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1-enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, 1-methyl-prop-1-enyl, 1-methylidenepropyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methyl-but-2-enyl. , 3-methyl-but-1-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl, 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methylidene-3-methylbutyl, 2,3-dimethyl-but-1-enyl, hexa-1,3-dienyl, hexa-1,4-dienyl, penta-1,4-dienyl, penta-1,3-dienyl, buta-1,3-dienyl, 2,3-dimethylbuta-1,3-dienyl, and the like.

[0216] The generic terms propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl, etc., unless any further definition is intended to mean all possible isomeric forms with the corresponding number of carbon atoms, i.e. propenyl includes prop-1-enyl and prop-2-enyl, butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, etc.

[0217] The alkenyl may optionally be in the cis or trans or E or Z configuration about the double bond.

[0218] The above definition of alkenyl also means that alkenyl is, for example, C x-y Alkenylamino or C x-y This also applies when it is part of another (combined) group, such as alkenyloxy.

[0219] Unlike alkylene, Alkenylene consists of at least two carbon atoms, where at least two adjacent carbon atoms are connected together by a CC double bond, and a carbon atom can only be part of one CC double bond. In an alkylene as defined herein above having at least two carbon atoms, when two hydrogen atoms on adjacent carbon atoms are formally removed and the free valences are saturated to form a second bond, the corresponding alkenylene is formed.

[0220] Examples of alkenylene are ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene, hexenylene, and the like.

[0221] The generic terms propenylene, butenylene, pentenylene, hexenylene etc., unless any further definition is intended to mean all the possible isomeric forms with the corresponding number of carbon atoms, i.e. propenylene includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 2-methylpropenylene, 1,1-dimethylethenylene and 1,2-dimethylethenylene.

[0222] Alkenylene may optionally be in the cis or trans or E or Z configuration about the double bond.

[0223] The above definition of alkenylene also applies when alkenylene is, for example, HO-C x-y Alkenyleneamino or H2N-C x-y This also applies when it is part of another (combined) group, such as alkenyleneoxy.

[0224] Unlike alkyl, Alkynyl consists of at least two carbon atoms, where at least two adjacent carbon atoms are connected together by a C-C triple bond. In an alkyl as defined hereinabove having at least two carbon atoms, two hydrogen atoms from any adjacent carbon atom are formally removed to saturate the free valences and form two additional bonds to form the corresponding alkynyl.

[0225] Examples of alkynyl are ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-1-ynyl, hex-1-ynyl, hex-2-ynyl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, and the like.

[0226] The generic terms propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc., unless any further definition is intended to mean all possible isomeric forms with the corresponding number of carbon atoms, i.e. propynyl includes prop-1-ynyl and prop-2-ynyl, butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-1-ynyl, 1-methyl-prop-2-ynyl, etc.

[0227] If the hydrocarbon chain also carries at least one double bond and at least one triple bond, then by definition this hydrocarbon chain belongs to an alkynyl moiety.

[0228] The above definition of alkynyl also means that alkynyl is, for example, C x-y Alkynylamino or C x-y This also applies when it is part of another (combined) group, such as alkynyloxy.

[0229] Unlike alkylene, Alkynylene consists of at least two carbon atoms, where at least two adjacent carbon atoms are connected together by a C-C triple bond. In an alkylene as defined hereinabove having at least two carbon atoms, when two hydrogen atoms of any adjacent carbon atom are formally removed and the free valences are saturated to form two additional bonds, the corresponding alkynylene is formed.

[0230] Examples of alkynylene are ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene, and the like.

[0231] The generic terms propynylene, butynylene, pentynylene, hexynylene, etc., unless any further definition is intended to mean all the possible isomeric forms with the corresponding number of carbon atoms, i.e., propynylene includes 1-methylethynylene, butynylene includes 1-methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene.

[0232] The above definition of alkynylene also applies when alkynylene is, for example, HO-C x-y Alkynyleneamino or H2N-C x-y This also applies when it is part of another (combined) group, such as alkynyleneoxy.

[0233] Heteroatoms means oxygen, nitrogen and sulfur atoms.

[0234] Haloalkyl (haloalkenyl, haloalkynyl) is derived from the alkyl (alkenyl, alkynyl) as defined above by the replacement of one or more hydrogen atoms of the hydrocarbon chain, independently of one another, by halogen atoms which may be identical or different. If a haloalkyl (alkenyl, haloalkynyl) is further substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all hydrogen-carrying carbon atoms.

[0235] Examples of haloalkyl (haloalkenyl, haloalkynyl) include -CF3, -CHF2, -CH2F, -CF2CF3, -CHFCF3, -CH2CF3, -CF2CH3, -CHFCH3, -CF2CF2CF3, -CF2CH2CH3, -CF=CF2, -CCl=CH2, -CBr=CH2, -C≡C-CF3, -CHFCH2CH3, -CHFCH2CF3, and the like.

[0236] From the haloalkyl (haloalkenyl, haloalkynyl) defined above: Haloalkylene (haloalkenylene, haloalkynylene)The term haloalkylene (haloalkenylene, haloalkynylene) is also derived. Haloalkyl (haloalkenyl, haloalkynyl) is different from haloalkyl (haloalkenyl, haloalkynyl) in that it is divalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from the haloalkyl (haloalkenyl, haloalkynyl).

[0237] Corresponding groups are, for example, -CH2F and -CHF-, -CHFCH2F and -CHFCHF- or >CFCH2F.

[0238] The above definitions also apply if the corresponding halogen-containing groups are part of another (combined) group.

[0239] halogen represents a fluorine, chlorine, bromine and / or iodine atom.

[0240] Cycloalkyl is composed of the subgroups monocyclic cycloalkyl, bicyclic cycloalkyl and spiro-cycloalkyl. The ring systems are saturated and are formed by linked carbon atoms. In bicyclic cycloalkyl, two rings are connected together in such a way that they share at least two carbon atoms. In spiro-cycloalkyl, one carbon atom (spiro atom) belongs to both rings together.

[0241] If a cycloalkyl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all hydrogen-carrying carbon atoms. Cycloalkyl itself, as a substituent, may be linked to the molecule via any suitable position of the ring system.

[0242] Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl (octahydroindenyl), bicyclo[4.4.0]decyl (decahydronaphthyl), bicyclo[2.2.1]heptyl (norbornyl), bicyclo[4.1.0]heptyl (norcaranyl), bicyclo[3.1.1]heptyl (pinanyl), spiro[2.5]octyl, spiro[3.3]heptyl, and the like.

[0243] The above definition of cycloalkyl also applies when cycloalkyl is, for example, C x-y Cycloalkylamino, C x-y Cycloalkyloxy or C x-y This also applies when it is part of another (combined) group, such as cycloalkylalkyl.

[0244] If the free valence of the cycloalkyl is saturated, alicyclic ring is obtained.

[0245] Cycloalkylene The term can therefore be derived from cycloalkyl as defined above. Cycloalkylene, unlike cycloalkyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a cycloalkyl. Corresponding groups are, for example: Cyclohexyl and [ka]

[0246] The above definition of cycloalkylene also applies when cycloalkylene is, for example, HO-C x-y Cycloalkyleneamino or H2N-C x-y This also applies when it is part of another (combined) group, such as cycloalkyleneoxy.

[0247] Cycloalkenyl is composed of the subgroups monocyclic cycloalkenyl, bicyclic cycloalkenyl and spiro-cycloalkenyl. However, this system is unsaturated, i.e., there is at least one C-C double bond, but no aromatic system. In a cycloalkyl as defined hereinbefore, two hydrogen atoms of adjacent cyclic carbon atoms are formally removed and the free valences are saturated to form a second bond, resulting in the corresponding cycloalkenyl.

[0248] If a cycloalkenyl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all hydrogen-carrying carbon atoms. The cycloalkenyl itself, as a substituent, may be linked to the molecule via any suitable position of the ring system.

[0249] Examples of cycloalkenyl are cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, cyclohex-1-enyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohept-1-enyl, cyclohept-2-enyl, cyclohept-3-enyl, cyclohept-4-enyl, cyclobuta-1,3-dienyl, cyclopenta -1,4-dienyl, cyclopenta-1,3-dienyl, cyclopenta-2,4-dienyl, cyclohexa-1,3-dienyl, cyclohexa-1,5-dienyl, cyclohexa-2,4-dienyl, cyclohexa-1,4-dienyl, cyclohexa-2,5-dienyl, bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl), bicyclo[2.2.1]hept-2-enyl (norbornenyl), spiro[4,5]dec-2-enyl, and the like.

[0250] The above definition of cycloalkenyl also applies when cycloalkenyl is, for example, C x-y Cycloalkenylamino, C x-y Cycloalkenyloxy or C x-yThis also applies when they are part of another (combined) group, such as cycloalkenylalkyl.

[0251] When the free valence of the cycloalkenyl is saturated, unsaturated alicyclic ring is obtained.

[0252] Cycloalkenylene The term can therefore be derived from cycloalkenyl as defined above. Cycloalkenylene, unlike cycloalkenyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from cycloalkenyl. Corresponding groups are, for example: Cyclopentenyl and [ka]

[0253] The above definition of cycloalkenylene also applies when cycloalkenylene is, for example, HO-C x-y Cycloalkenyleneamino or H2N-C x-y This also applies when it is part of another (combined) group, such as cycloalkenyleneoxy.

[0254] Aryl represents a monocyclic, bicyclic or tricyclic carbocycle having at least one aromatic carbocycle. Preferably, aryl represents a monocyclic group having 6 carbon atoms (phenyl) or a bicyclic group having 9 or 10 carbon atoms (two 6-membered rings or one 6-membered and one 5-membered ring), where the second ring may be aromatic but may also be partially saturated.

[0255] If an aryl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all hydrogen-carrying carbon atoms. The aryl itself, as a substituent, may be linked to the molecule via any suitable position of the ring system.

[0256] Examples of aryl are phenyl, naphthyl, indanyl (2,3-dihydroindenyl), indenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl (1,2,3,4-tetrahydronaphthyl, tetralinyl), dihydronaphthyl (1,2-dihydronaphthyl), fluorenyl, etc. Most preferred is phenyl.

[0257] The above definition of aryl also applies if aryl is part of another (combined) group, such as, for example, arylamino, aryloxy or arylalkyl.

[0258] If the free valence of the aryl is saturated, aromatic group is obtained.

[0259] Arylene The term may also be derived from aryl as defined above. Arylene, unlike aryl, is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from an aryl. Corresponding groups are, for example: Phenyl and [ka] Naphthyl and [ka]

[0260] The above definition for arylene also applies if arylene is part of another (combined) group, such as, for example, HO-aryleneamino or H2N-aryleneoxy.

[0261] Heterocyclylrepresents a ring system derived from the above-defined cycloalkyl, cycloalkenyl and aryl by replacing one or more of the -CH2- groups, independently of one another, in the hydrocarbon ring by the group -O-, -S- or -NH-, or by replacing one or more of the =CH- groups by the group =N-, where up to 5 heteroatoms may be present in total, at least one carbon atom must be present between two oxygen atoms and two sulfur atoms or between an oxygen atom and a sulfur atom, and the ring as a whole must have chemical stability. The heteroatoms may optionally be present in all possible oxidation stages (sulfur → sulfoxide-SO-, sulfone-SO2-; nitrogen → N-oxide). In heterocyclyl, there is no heteroaromatic ring, i.e. the heteroatoms are not part of the aromatic system.

[0262] A direct consequence of the derivation from cycloalkyl, cycloalkenyl, and aryl is that heterocyclyl is comprised of the subgroups monocyclic heterocyclyl, bicyclic heterocyclyl, tricyclic heterocyclyl, and spiro-heterocyclyl, which may exist in saturated or unsaturated form.

[0263] Unsaturated means that there is at least one double bond in the ring system, but no heteroaromatic system is formed. In a bicyclic heterocyclyl, two rings are linked together to share at least two (hetero)atoms. In a spiro-heterocyclyl, one carbon atom (spiro atom) belongs to both rings together.

[0264] When a heterocyclyl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all hydrogen-carrying carbon and / or nitrogen atoms. The heterocyclyl itself may be linked to the molecule as a substituent via any suitable position of the ring system. For the substituents on the heterocyclyl, the number of members of the heterocyclyl is not critical.

[0265] Examples of heterocyclyls are tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, thiazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, oxiranyl, aziridinyl, azetidinyl, 1,4-dioxanyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-di. Oxide, 1,3-dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, [1,4]-oxazepanyl, tetrahydrothienyl, homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridyl, dihydro-pyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-S-oxide, tetrahydrothienyl-S,S-dioxide, homothiomorpholinyl-S-oxide cido, 2,3-dihydroazeto, 2H-pyrrolyl, 4H-pyranyl, 1,4-dihydropyridinyl, 8-aza-bicyclo[3.2.1]octyl, 8-aza-bicyclo[5.1.0]octyl, 2-oxa-5-azabicyclo[2.2.1]heptyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, 3,8-diaza-bicyclo[3.2.1]octyl, 2,5-diaza-bicyclo[2.2.1]heptyl, 1-aza-bicyclo[2.2.2]octyl, 3,8-diaza- Bicyclo[3.2.1]octyl, 3,9-diaza-bicyclo[4.2.1]nonyl, 2,6-diaza-bicyclo[3.2.2]nonyl, 1,4-dioxa-spiro[4.5]decyl, 1-oxa-3,8-diaza-spiro[4.5]decyl, 2,6-diaza-spiro[3.3]heptyl, 2,7-diaza-spiro[4.4]nonyl, 2,6-diaza-spiro[3.4]octyl, 3,9-diaza-spiro[5.5]undecyl, 2.8-diaza-spiro[4,5]decyl, etc.

[0266] Further examples are the structures illustrated below, which may be bonded (exchanged with hydrogen) through each hydrogen-bearing atom: [ka] TIFF2024543982000027.tif238165 TIFF2024543982000028.tif241165 TIFF2024543982000029.tif55165

[0267] Preferred monocyclic heterocyclyls are 4-7 membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur.

[0268] Preferred monocyclic heterocyclyls are piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, and azetidinyl.

[0269] Preferred bicyclic heterocyclyls are 6-10 membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur.

[0270] Preferred tricyclic heterocyclyls are 9-membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur.

[0271] Preferred spiro-heterocyclyls are 7-11 membered and have 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur.

[0272] The above definition of heterocyclyl also applies if heterocyclyl is part of another (combined) group, such as, for example, heterocyclylamino, heterocyclyloxy or heterocyclylalkyl.

[0273] If the free valence of the heterocyclyl is saturated, Heterocycle is obtained.

[0274] HeterocyclyleneThe term is also derived from heterocyclyl as defined above. Heterocyclylene, unlike heterocyclyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heterocyclyl. Corresponding groups are, for example: Piperidinyl and [ka] 2,3-Dihydro-1H-pyrrolyl and [ka]

[0275] The above definition of heterocyclylene also applies if heterocyclylene is part of another (combined) group, such as, for example, HO-heterocyclyleneamino or H2N-heterocyclyleneoxy.

[0276] Heteroaryl represents a monocyclic heteroaromatic ring or a polycyclic ring having at least one heteroaromatic ring, which contains, in place of one or more carbon atoms, one or more identical or different heteroatoms selected from among nitrogen, sulfur and oxygen, in comparison with the corresponding aryl or cycloalkyl(alkenyl), where the resulting group must be chemically stable. The prerequisite for the presence of heteroaryl is the heteroatom and the heteroaromatic system.

[0277] When heteroaryl is substituted, the substitutions can be carried out independently of one another, in the form of monosubstitution or polysubstitution in each case, on all hydrogen-carrying carbon and / or nitrogen atoms.Heteroaryl itself can be linked to the molecule as a substituent at any suitable position of the ring system, i.e., via both carbon and nitrogen.For the substituent on heteroaryl, the number of members of heteroaryl is not important.

[0278] Examples of heteroaryl are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyridyl-N-oxide, pyrrolyl-N-oxide, pyrimidinyl-N-oxide, pyridazinyl-N-oxide, pyrazinyl-N-oxide, imidazolyl-N-oxide, isoxazolyl-N-oxide, oxazolyl-N-oxide, thiazolyl-N-oxide, oxadiazolyl-N-oxide, thiadiazolyl-N-oxide, triazolyl-N-oxide, tetrazolyl-N-oxide, indolyl, isoindolyl, benzofuryl, benzothienyl, benzoxazolyl, benzo zothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl, benzotriazinyl, indolizinyl, oxazolopyridyl, imidazopyridyl, naphthyridinyl, benzoxazolyl, pyridopyridyl, pyrimidopyridyl, purinyl, pteridinyl, ben These include zothiazolyl, imidazopyridyl, imidazothiazolyl, quinolinyl-N-oxide, indolyl-N-oxide, isoquinolyl-N-oxide, quinazolinyl-N-oxide, quinoxalinyl-N-oxide, phthalazinyl-N-oxide, indolizinyl-N-oxide, indazolyl-N-oxide, benzothiazolyl-N-oxide, and benzimidazolyl-N-oxide.

[0279] Further examples are the structures illustrated below, which may be bonded (exchanged with hydrogen) through each hydrogen-bearing atom: [ka]

[0280] Preferably, the heteroaryl is a 5- to 6-membered monocyclic or 9- to 10-membered bicyclic ring, each having 1 to 4 heteroatoms independently selected from oxygen, nitrogen and sulfur.

[0281] The above definition of heteroaryl also applies if heteroaryl is part of another (combined) group, such as, for example, heteroarylamino, heteroaryloxy or heteroarylalkyl.

[0282] If the free valence of the heteroaryl is saturated, Heteroaromatic groups is obtained.

[0283] Heteroarylene The term is also derived from heteroaryl as defined above. Heteroarylene, unlike heteroaryl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heteroaryl. Corresponding groups are, for example: Pyrrolyl and [ka]

[0284] The above definition of heteroarylene also applies if heteroarylene is part of another (combined) group, such as, for example, HO-heteroaryleneamino or H2N-heteroaryleneoxy.

[0285] Has been replaced means that a hydrogen atom directly bonded to the atom under consideration is replaced by another atom or a group of another atom (substituent). Depending on the starting conditions (number of hydrogen atoms), mono- or polysubstitutions can be made on an atom. Substitution with a specific substituent is only possible if the allowed valences of the substituent and the allowed valences of the atom to be replaced correspond to each other and the substitution leads to a stable compound (i.e., a compound that is not spontaneously transformed, for example, by rearrangement, cyclization or elimination).

[0286] Divalent substituents such as =S, =NR, =NOR, =NNRR, =NN(R)C(O)NRR, =N2, etc. are only possible as substituents on carbon atoms, but the divalent substituents =O and =NR can also be substituents on sulfur. In general, substitutions can only be made on ring systems by divalent substituents and require the replacement of two geminal hydrogen atoms, i.e. hydrogen atoms attached to the same carbon atom that is saturated before the substitution. Thus, substitutions by divalent substituents are only possible on the group -CH2- or sulfur atoms of the ring system (only =O or =NR groups, one or two =O groups are possible, or, for example, one =O and one =NR group, each group replacing a free electron pair).

[0287] Isotopes: Any disclosure of atoms or compounds of the present invention should be understood to include all suitable isotopic variations, specifically reference to hydrogen also includes deuterium.

[0288] Stereochemistry / solvates / hydrates: Unless specifically indicated, throughout this specification and the appended claims, a given chemical formula or name is intended to encompass tautomers and all stereo, optical, and geometric isomers (e.g., enantiomers, diastereomers, E / Z isomers, etc.) thereof, as well as racemates, as well as mixtures of the separate enantiomers in differing proportions, mixtures of diastereomers, or mixtures of any of the foregoing forms, where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts, and solvates thereof, such as solvates and hydrates of the free compounds or of a salt of the compounds, including solvates and hydrates.

[0289] In general, substantially pure stereoisomers can be obtained according to synthetic principles known to those skilled in the art, for example, by separation of the corresponding mixtures, by the use of stereochemically pure starting materials and / or by stereoselective synthesis. It is known in the art how to prepare optically active forms, for example, by resolution of racemates or by synthesis, for example, starting from optically active starting materials and / or using chiral reagents.

[0290] Enantiomerically pure compounds or intermediates of the present invention may be prepared via asymmetric synthesis, for example by the preparation and subsequent separation of suitable diastereomeric compounds or intermediates which can be separated by known methods (e.g. chromatographic separation or crystallization), and / or by the use of chiral reagents, such as chiral starting materials, chiral catalysts or chiral auxiliaries.

[0291] Furthermore, methods for preparing enantiomerically pure compounds from the corresponding racemic mixtures are also known to the skilled artisan, for example by chromatographic separation of the corresponding racemic mixtures on chiral stationary phases, or by resolution of the racemic mixtures using suitable resolving agents, for example by formation of diastereomeric salts of the racemates with optically active acids or bases followed by resolution of the salts and liberation of the desired compound from the salts, or by derivatization of the corresponding racemates with optically active chiral auxiliary reagents followed by diastereomeric separation and removal of the chiral auxiliary, or by kinetic resolution of the racemates (for example enzymatic resolution); by enantioselective crystallization from a consortium of enantiomeric crystals under suitable conditions, or by (fractional) crystallization from a suitable solvent in the presence of an optically active chiral auxiliary.

[0292] salt: The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, and are commensurate with a reasonable benefit / risk ratio.

[0293] As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.

[0294] For example, such salts include salts from benzenesulfonic acid, benzoic acid, citric acid, ethanesulfonic acid, fumaric acid, gentisic acid, hydrobromic acid, hydrochloric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, 4-methyl-benzenesulfonic acid, phosphoric acid, salicylic acid, succinic acid, sulfuric acid, and tartaric acid.

[0295] Further pharma- ceutically acceptable salts can be formed with cations from ammonia, L-arginine, calcium, 2,2'-iminobisethanol, L-lysine, magnesium, N-methyl-D-glucamine, potassium, sodium and tris(hydroxymethyl)-aminomethane.

[0296] The pharma- ceutically acceptable salts of the present invention can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or free base form of these compounds with a sufficient amount of the appropriate base or acid in water or an organic diluent such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.

[0297] For example, salts of acids other than those mentioned above that are useful in the purification or isolation of the compounds of this invention (eg, trifluoroacetates) also form part of this invention.

[0298] for example, [ka] In depictions such as these, the letter A serves the function of designating a ring for easier reference, for example to indicate the attachment of that ring to another ring.

[0299] For divalent groups, it is very important to determine which adjacent group it is bonded to and with what valency, and the corresponding bond partner is shown in parentheses for clarity, where necessary, as in the following depiction: [ka] or (R 2 )-C(=O)NH- or (R 2 )-NHC(=O)-.

[0300] Unless such clarification is given, divalent groups can be attached in both orientations, i.e., for example, -C(=O)NH- also includes -NHC(=O)- and vice versa.

[0301] A group or substituent often refers to a number of alternative groups / substituents for which the corresponding group is designated (e.g., R a , R b etc.) When such groups are used repeatedly in different parts of the molecule to define the compounds according to the invention, it is implied that the various uses should be considered completely independent of each other.

[0302] A therapeutically effective amount for purposes of this invention means an amount of a substance that is capable of eliminating symptoms of a disease, preventing or alleviating these symptoms, or prolonging the survival of the treated patient.

[0303] List of abbreviations [Table 1] TIFF2024543982000037.tif244161 TIFF2024543982000038.tif235161 EXAMPLES

[0304] The features and advantages of the present invention will become apparent from the following detailed examples which illustrate, by way of example, the principles of the invention without limiting its scope:

[0305] Preparation of the Compounds of the Invention overview Unless otherwise specified, all reactions are carried out in commercially available equipment using methods commonly used in chemical laboratories. Air- and / or moisture-sensitive starting materials are stored under protective gas and the corresponding reactions and manipulations are carried out under protective gas (nitrogen or argon).

[0306] When a compound is represented by both a structural formula and its nomenclature, in case of conflict, the structural formula shall be determining.

[0307] Microwave reactions are carried out in a Biotage synthesizer / reactor or a CEM Explorer or an Anton Paar Synthos 3000 or Monowave 3000 in a closed vessel (preferably 2, 5 or 20 mL), preferably with stirring.

[0308] Chromatography Thin layer chromatography is performed on Merck pre-made silica gel 60 TLC glass plates (with fluorescent indicator F-254).

[0309] Preparative high pressure chromatography (RP HPLC) of the exemplary compounds according to the present invention is carried out on an Agilent or Gilson system using columns manufactured by Waters (designation: SunFire™ Prep C18, OBD™ 10 μm, 50×150 mm or SunFire™ Prep C18 OBD™ 5 μm, 30×50 mm or XBridge™ Prep C18, OBD™ 10 μm, 50×150 mm or XBridge™ Prep C18, OBD™ 5 μm, 30×150 mm or XBridge™ Prep C18, OBD™ 5 μm, 30×50 mm) and columns manufactured by YMC (designation: Actus-Triart Prep C18, 5 μm, 30×50 mm).

[0310] Elute the compounds using different gradients of HO / acetonitrile, but for the Agilent system, add 5% acidity modifier (20 mL HCOOH to 1 L HO / acetonitrile (1 / 1)) to water (acidic conditions); for the Gilson system, add water to 0.1% HCOOH.

[0311] For chromatography under basic conditions on the Agilent system, the same H2O / acetonitrile gradient is used, but the water is made alkaline by adding 5% basic modifier (50 g NH4HCO3 + 50 mL NH3 (25% in H2O) to 1 L with H2O). For the Gilson system, the water is made alkaline as follows: 5 mL NH4HCO3 solution (158 g in 1 L H2O) and 2 mL NH3 (28% in H2O) made up to 1 L with H2O.

[0312] Supercritical fluid chromatography (SFC) of the intermediates and exemplary compounds of the present invention is performed on a JASCO SFC system using the following columns: Chiralcel OJ (250×20 mm, 5 μm), Chiralpak AD (250×20 mm, 5 μm), Chiralpak AS (250×20 mm, 5 μm), Chiralpak IC (250×20 mm, 5 μm), Chiralpak IA (250×20 mm, 5 μm), Chiralcel OJ (250×20 mm, 5 μm), Chiralcel OD (250×20 mm, 5 μm), Phenomenex Lux C2 (250×20 mm, 5 μm).

[0313] Analytical HPLC (reaction control) of intermediates and final compounds is carried out using columns from Waters (designation: XBridge™ C18, 2.5 μm, 2.1×20 mm or XBridge™ C18, 2.5 μm, 2.1×30 mm or Aquity UPLC BEH C18, 1.7 μm, 2.1×50 mm) and columns from YMC (designation: Triart C18, 3.0 μm, 2.0×30 mm) and columns from Phenomenex (designation: Luna C18, 5.0 μm, 2.0×30 mm). The analytical instruments are also equipped in each case with a mass detector.

[0314] HPLC mass spectrometry / UV spectroscopy Retention Time / MS-ESI for Characterizing Exemplary Compounds of the Present Invention + is generated using an HPLC-MS instrument (high performance liquid chromatography equipped with a mass detector). Compounds eluting in the injection peak have retention times t Ret. =0.00.

[0315] Method A HPLC Agilent 1100 System MS 1200Series LC / MSD(API-ES+ / -3000V, Quadrupol, G6140) MSD signal settings Scan positive / negative 120~900m / z Detection signal: 315 nm (bandwidth 170 nm, reference off) Spectral range: 230-400nm Peak width <0.01 min Column: Waters, Xbridge C18, 2.5μm, 2.1×20mm column Column temperature: 60℃ Solvent A: 20mM NH4HCO3 / NH3 in H2O pH 9 B:ACN HPLC grade Flow rate 1.00mL / min Gradient 0.00~1.50min 10%~95% B 1.50~2.00 minutes 95% B 2.00~2.10 minutes 95%~10% B

[0316] Method B HPLC Agilent 1260 System MS 1200 Series LC / MSD(MM-ES+APCI+ / -3000V, Quadrupol, G6130) Detection UV: 254 nm (bandwidth 8, reference off) UV: 230nm (bandwidth 8, reference off) UV spectrum range: 190~400nm; Step: 4nm MS: positive and negative modes Mass range: 100-800m / z Column: Waters; Part. No. 186003389; XBridge BEH C18, 2,5μm, 30×2.1mm Column temperature: 45℃ Solvent A: 5mM NH4HCO3 / 19mM NH3 (in H2O); B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00~1.00min: 5% B~100% B 1.00~1.37 minutes: 100% B 1.37~1.40 minutes: 100% B~5% B

[0317] Method C HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range 100~750m / z Column: Waters X-Bridge BEH C18, 2.5μm, 2.1×30mm XP Column temperature: 45℃ Solvent A: 20mM NH4HCO3 / 30mM NH3 (in H2O); B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00~1.00 min: 15% B~95% B 1.00~1.30 minutes: 95% B

[0318] Method D HPLC Agilent 1100 / 1200 Systems MS 1200 Series LC / MSD(MM-ES+APCI+ / -3000V, Quadrupol, G6130B) MSD Signal Settings Scan Positive 150~750 Detection signal UV 254nm, 230nm, 214nm (bandwidth 8, reference off) Spectral range: 190~400nm; Slit: 4nm Peak width >0.0031 min (0.063 s response time, 80 Hz) Column: Waters, Part. No. 186003389, XBridge BEH C18, 2.5 μm, 2.1 × 30 mm) column Column temperature: 45℃ Solvent A: 5mM NH4HCO3 / 18mM NH3 in H2O (pH=9.2) B:ACN (HPLC grade) Flow rate 1.4mL / min Gradient 0.0~1.0min 15%~95% B 1.0~1.1 minutes 95% B Downtime: 1.3 minutes

[0319] Method E HPLC Agilent 1100 / 1200 Systems MS 1200 Series LC / MSD(MM-ES+APCI+ / -3000V, Quadrupol, G6130B) MSD Signal Settings Scan Positive / Negative 150~750 Detection signal UV 254nm, 230nm, 214nm (bandwidth 8, reference off) Spectral range: 190~400nm; Slit: 4nm Peak width >0.0031 min (0.063 s response time, 80 Hz) Column: Waters, Part. No. 186003389, XBridge BEH C18, 2.5 μm, 2.1 × 30 mm) column Column temperature: 45℃ Solvent A: 5mM NH4HCO3 / 18mM NH3 in H2O (pH=9.2) B:ACN (HPLC grade) Flow rate 1.4mL / min Gradient 0.0~1.0min 15%~95% B 1.0~1.1 minutes 95% B Downtime: 1.3 minutes

[0320] Method F HPLC Agilent 1100 / 1200 Systems MS 1200 Series LC / MSD(API-ES+ / -3000 / 3500V, Quadrupol, G6140A) MSD Signal Settings Scan Positive / Negative 150~750 Detection signal UV 254nm, 230nm, 214nm (bandwidth 10, reference off) Spectral range: 190~400nm; Slit: 4nm Peak width >0.0031 min (0.063 s response time, 80 Hz) Column YMC; Part. No. TA12S03-0302WT; Triart C18, 3μm, 12nm; 30×2.0mm column Column temperature: 45℃ Solvent A: H2O + 0.11% formic acid B:ACN+0,1% formic acid (HPLC grade) Flow rate 1.4mL / min Gradient 0.0~1.0min 15%~95% B 1.0~1.1 minutes 95% B Downtime: 1.23 minutes

[0321] Method G UPLC-MS Waters Acquity-UPLC-SQ Detector-2 MSD signal settings: Scan positive & negative 100-1500, source voltage: capillary voltage (kV) -3.50, cone (V): 50, source temperature: desolvation temperature (℃): 350, raw gas flow rate: desolvation (L / h): 750, cone (L / h): 50 Detection signal Diode Array Spectral range: 200~400nm; Resolution: 1.2nm Sampling speed: 10 points / sec Column: AQUITY UPLC BEH C18 1.7μm, 2.1×50mm Column temperature: 35℃ Solvent A: 0.07% formic acid in ACN B: 0.07% formic acid (in water) Flow rate 0.6mL / min Gradient 0.0~0.30 min 97% B 0.30~2.20 minutes 97%~2% B 2.20~3.30 minutes 2% B 3.30~4.50 minutes 2%~97% B 4.50~4.51 minutes 97% B

[0322] Method H UPLC-MS Waters Acquity-Binary Solvent Manager-UPLC-SQ Detector-2 MSD signal settings: Scan positive & negative 100-1500, source voltage: capillary voltage (kV) -3.50, cone (V): 50, source temperature: desolvation temperature (℃): 350, raw gas flow rate: desolvation (L / h): 750, cone (L / h): 50 Detection signal Diode Array Spectral range: 200~400nm; Resolution: 1.2nm Sampling speed: 10 points / sec Column: AQUITY UPLC BEH C18 1.7μm, 2.1×50mm Column temperature: 35℃ Solvent A: 0.07% formic acid in ACN B: 0.07% formic acid (in water) Flow rate 0.6mL / min Gradient 0.0~0.40min 97% B 0.40~2.50 minutes 97%~2% B 2.50~3.40 minutes 2% B 3.40~3.50 minutes 2%~97% B 3.50~4.0 minutes 97% B

[0323] Method I LC-MS Waters Arc-HPLC-SQ Detector-2 MSD signal settings: ESI scan positive & negative, capillary voltage 3.50Kv, cone voltage 30V, desolvation gas 750L / hr, desolvation temperature 350℃ Column: X-Bridge C18, 4.6×75mm, 3.5μ Column temperature: 35℃ Solvent A: 10 mM ammonium acetate (in water) B:ACN Flow rate 1.0mL / min Gradient 0.0~0.75min 5% B 0.75~1.50 minutes 5%~40% B 1.50~5.0 minutes 40%~98% B 5.0~7.0 minutes 98% B

[0324] Method J LC-MS Waters Acquity-UPLC-SQ Detector-2 MSD signal settings ESI scan positive & negative Capillary voltage 3.50Kv Cone voltage 50V Desolvation gas 750L / h Desolvation temperature 350℃ Column: Waters Acquity-UPLC-SQ Detector-2 Column temperature: 35℃ Solvent A: 0.05% TFA in ACN B:0.05% TFA (in water) Flow rate 0.6mL / min Gradient 0.0~0.3 min 97% B 0.3~2.2 minutes 97%~2% B 2.2~3.3 minutes 2% B

[0325] Method K LC-MS Waters Arc-HPLC-SQ Detector-2 MSD signal settings: ESI scan positive & negative, capillary voltage 3.50Kv, cone voltage 30V, desolvation gas 750L / hr, desolvation temperature 350℃ Column: X-Bridge C18, 4.6×50mm, 3.5μ Column temperature: 35℃ Solvent A: 10 mM ammonium acetate (in water) B:ACN Flow rate 2.0mL / min Gradient 0.0~0.2min 10% B 0.2~2.50 minutes 10%~75% B 2.50~3.0 minutes 75%~100% B 3.0~4.8 minutes 100% B

[0326] Method L HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range: 550-1200m / z Column: Waters X-Bridge BEH C18, 2.5μm, 2.1×30mm XP Column temperature: 45℃ Solvent A: 20mM NH4HCO3 / 30mM NH3 (in H2O); B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00~1.50 min: 50% B~95% B 1.50~2.00 minutes: 95% B

[0327] Method M HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range: 550-1200m / z Column: Waters X-Bridge BEH C18, 2.5μm, 2.1×30mm XP Column temperature: 45℃ Solvent A: 20mM NH4HCO3 / 30mM NH3 (in H2O); B: ACN (HPLC grade) Flow rate 1.40mL / min Gradient 0.00~1.00 min: 50% B~95% B 1.00~1.30 minutes: 95% B

[0328] Method N HPLC Agilent 1260 Series MS Agilent LC / MSD Quadrupole Detection MS: positive and negative modes Mass range 100~750m / z Column: YMC-Triart C18, 3μm, 12nm, 2.0×30mm Column temperature: 45℃ Solvent A: H2O + 0.11% formic acid; B: ACN (HPLC grade) + 0.1% formic acid Flow rate: 1.40mL / min Gradient: 0.00-1.00 min: 15% B-95% B 1.00~1.30 minutes: 95% B

[0329] Method O HPLC Waters - Alliance 2996 Detection signal PDA Detector Spectral range: 200~400nm; Resolution: 1.2nm Sampling speed: 1 point / sec ELSD parameters Gas pressure: 50 PSI, Drift tube temperature: 50°C, Gain: 500 Column: Atlantis T3 (4.6 x 250 mm) 5.0 μm Column temperature Ambient temperature Solvent A: 10 mM ammonium acetate (in water) B:ACN Flow rate 0.7mL / min Gradient 0.0~1.20min 2% B 1.2~10.0 minutes 2%~98% B 10.0~12.0 minutes 98% B 12.0~14.0 minutes 97%~2% B 14.0~16.0 minutes 2% B

[0330] Method P UPLC-MS Waters Acquity-UPLC-SQ Detector-2 MSD signal settings: Scan positive & negative 100-1500, source voltage: capillary voltage (kV) -3.50, cone (V): 50, source temperature: desolvation temperature (℃): 350, raw gas flow rate: desolvation (L / hour): 650 Detection signal Diode Array Spectral range: 200~400nm; Resolution: 1.2nm Sampling speed: 10 points / sec ELSD parameters: GAS: 2.0 SLM, nebulizer temperature: 40°C, evaporation temperature: 45°C Column: AQUITY UPLC BEH C18 1.7μm, 2.1×50mm Column temperature: 50℃ Solvent A: 0.05% formic acid in water B: 0.05% formic acid (in ACN) Flow rate 0.6mL / min Gradient 0.0~2.20min 3%~98% B 2.20~3.20 minutes 98% B 3.20~3.50 minutes 98%~3% B 3.50~4.20 minutes 2% B

[0331] Method Q HPLC-MS 2998PDA Detector and Waters Arc-HPLC equipped with SQ Detector-2 MSD signal settings: Scan positive & negative 100-1500, source voltage: capillary voltage (kV) -3.50, cone (V): 30, source temperature: desolvation temperature (℃): 350, raw gas flow rate: desolvation (L / h): 750 Detection signal PDA Detector Spectral range: 200~400nm; Resolution: 1.2nm Sampling speed: 10 points / sec Column: X-Bridge C18, 4.6×50mm, 3.5μm Column temperature: 35℃ Solvent A: 10 mM ammonium acetate (in water) B:ACN Flow rate 1.0mL / min Gradient 0.0~0.75min 5% B 0.75~1.50 minutes 5%~40% B 1.50~5.0 minutes 40%~98% B 5.0~7.0 minutes 98% B 7.0~9.0 minutes 98%~5% B 9.0~10.01 minutes 5% B

[0332] Method R HPLC Agilent 1200 System Column: Chiralpak IE, 5.0μm, 2.1×150mm column Column temperature: 40℃ Solvent: EtOH / heptane 1:1 + 0.1% diethylamine (isoconcentrated) Flow rate 0.60mL / min

[0333] GCMS Method U Agilent Technologies-7890B GC system equipped with GC 7693 Auto Sampler and 5977A MSD Injection temperature 230℃ Column flow rate: 2.0 mL / min Solvent delay 1.5 min Split ratio 10:01 Column oven temperature program: 100°C / 1 min, 20°C / min / 310° / 5 min Total running time: 16 minutes Interface temperature 150℃ Ion source temperature: 230℃ Gas He Column & Column dimensions ZB-5MS (30m x 0.32mm; 1μm) MSD scan range 50~900

[0334] Method V Agilent Technologies-7890B GC system equipped with GC 7693 Auto Sampler and 5977A MSD Injection temperature 230℃ Column flow rate: 2.0 mL / min Solvent delay 1.5 min Split ratio 10:01 Column oven temperature program: 40°C / 2 min, 15°C / min / 200° / 1 min, 25°C / min / 310° / 0 min Total running time: 18 minutes Interface temperature 150℃ Ion source temperature: 230℃ Gas He Column & Column dimensions ZB-5MS (30m x 0.32mm; 1μm) MSD scan range 50~900

[0335] Method W Agilent Technologies-7890B GC system equipped with GC 7693 Auto Sampler and 5977A MSD Injection temperature 230℃ Column flow rate: 2.0 mL / min Solvent delay 1.5 min Split ratio 10:01 Column oven temperature program: 60°C / 3 min, 20°C / min / 310° / 2 min Total running time: 18 minutes Interface temperature 150℃ Ion source temperature: 230℃ Gas He Column & Column dimensions ZB-5MS (30m x 0.32mm; 1μm)

[0336] Method SFC-1 Manufacturer Waters UPC 2 -MS Software Empower3 MS QDa Column CHIRALCEL OX-3(4.6 * 150MM) 3μm A-solvent CO2 B-solvent ACN Total flow rate: 3g / min % of co-solvent 15 ABPR 500psi Column temperature: 30℃ PDA range 200nm~400nm Resolution 1.2nm MS parameters - QDa MS scan range 100Da~1000Da Cone Voltage Positive scan 20V Negative scan 15V

[0337] The compounds and intermediates according to the invention are prepared by the synthetic methods described below in this specification, in which the substituents of the general formula have the meanings given herein above. These methods are intended as illustrations of the invention, and the subject matter and scope of the claimed compounds are not limited to these examples. Where the preparation of starting compounds is not described, they may be commercially available or their synthetic methods are described in the prior art, or may be prepared analogously to known prior art compounds or methods described herein, i.e., it is within the skill of an organic chemist to synthesize these compounds. Substances described in the literature can be prepared according to published synthetic methods. Hereinafter, when chemical structures are depicted without the exact configuration of stereocenters, e.g., asymmetrically substituted carbon atoms, both configurations shall be considered to be included and disclosed in such depiction. The depiction of stereocenters in racemates shall always be considered to include and disclose both enantiomers (if no other defined stereocenters exist) or all other potential diastereomers and enantiomers (if further defined or undefined stereocenters exist).

[0338] Synthesis of spiroketone intermediate A Experimental procedure for the synthesis of A-2a [ka] To a suspension of 5-chloropentanenitrile (22.9 g, 195 mmol, 1.00 equiv) in EtOH (136 mL) was added acetyl chloride (111 mL, 1.56 mol, 8.00 equiv) dropwise at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 12 h. The mixture was concentrated under reduced pressure, washed with EtO, and the crude product A-2a was used directly as the HCl salt in the next step without further purification (HPLC method: A;t ret =1.03 minutes;[M+H] + =164).

[0339] Experimental procedure for the synthesis of A-3a [ka] Crude A-2a (HCl salt) (28.0 g, 140 mmol, 1.00 equiv) and ethylene glycol (7.38 g, 119 mmol, 0.90 equiv) were dissolved in DCM (300 mL) and stirred at room temperature for 6 days. The resulting suspension was concentrated under reduced pressure, diluted with Et2O (200 mL) and filtered. The filtrate was concentrated under reduced pressure, dissolved in DCM (200 mL) and treated with KOH solution (2 M in water, 150 mL). The mixture was stirred at room temperature overnight, keeping the phase intact. The phases were separated, the aqueous phase was extracted with DCM (2x) and the combined organic phases were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude orthoester A-3a was used in the next step without further purification (HPLC method: A;t ret =1.37 minutes;[M+H] + =163).

[0340] Experimental procedure for the synthesis of A-4a [ka] Crude A-3a (22.3 g, 107 mmol, 1.00 equiv), 1-cyclohexenyloxytrimethylsilane (16.4 mL, 82.3 mmol, 0.80 equiv) and zinc chloride (10.2 g, 74.8 mmol, 0.70 equiv) were dissolved in DCM (120 mL) and stirred at room temperature for 5 h. The reaction mixture was treated by addition of saturated sodium bicarbonate solution. The organic phase was separated, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by NP-chromatography to give the desired compound A-4a (HPLC method: A;t ret = 1.25 min; [M+Na] + =283).

[0341] Experimental procedure for the synthesis of A-8a [ka] A-4a (14.9 g, 57.1 mmol, 1.0 equiv.) and sodium iodide (26.0 g, 171 mmol, 3.0 equiv.) were dissolved in acetone (120 mL) and stirred under reflux for 16 h. The reaction mixture was concentrated under reduced pressure, diluted with DCM, and washed with saturated sodium thiosulfate solution. The organic phase was separated, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product A-5a was used in the next step without further purification.

[0342] A-5a (30 g, 85.0 mmol, 1.0 equiv.) was dissolved in THF. The mixture was treated with potassium tert.-butoxide (28.7 g, 256 mmol, 3.0 equiv.) at 0° C. and stirred at room temperature overnight. The reaction mixture was quenched by the addition of water (2 mL) and diluted by the addition of Et2O and saturated sodium bicarbonate solution. The organic phase was separated, dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was purified by NP chromatography to give (racemic) compound A-6a (the reaction sequence A-1a → A-6a is based on Marko et al., THL 2003, 44, 3333-3336 and Maulide et al., Eur. J. Org. Chem. 2004, 19:3962-3967).

[0343] Enantiomer A-6b could then be obtained after chiral separation by SFC using the following conditions: Column: Lux; Cellulose-4 (250 mm x 30 mm x 5 μm), 90% CO2, 10% ACN, Flow rate: 90 g / min, Temperature: 30 °C, Enantiomer A-6b as peak 2 after enantiomer elution (SFC method: SFC-1, t ret =2.99 minutes).

[0344] Synthesis of Alcohol-Intermediate B Experimental procedure for the synthesis of B-2a [ka] B-1a (4.92 g, 19.1 mmol, 1.00 equiv), N,N-carbonyldiimidazole (5.14 g, 28.6 mmol, 1.50 equiv) and molecular sieves (3 Å, 500 mg) were dissolved in DCM (29.5 mL) and stirred at room temperature for 40 min. After complete activation, N,O-dimethylhydroxylamine hydrochloride (2.79 g, 28.6 mmol, 1.50 equiv) was added and the reaction was stirred again at room temperature for 2 h. Upon completion, water (100 mL) and DCM (150 mL) were added, the phases were separated and the aqueous phase was extracted with DCM (2×). The combined organic phase was washed with brine and concentrated under reduced pressure. The residue was purified by NP chromatography to give product B-2a.

[0345] The following intermediate B-2 (Table 1) can be accessed in an analogous manner: The crude product is purified by chromatography if necessary. [Table 2]

[0346] Experimental procedure for the synthesis of B-3a [ka] B-2a (4.88 g, 16.9 mmol, 1.00 equiv) was dissolved in THF (15 mL) under argon atmosphere and cooled to -10°C. Bromo(methyl)magnesium (3.4 M in MeTHF, 6.46 mL, 22.0 mmol, 1.3 equiv) was added and stirred at -10°C for 1 h. After complete conversion, the reaction mixture was cooled to -20°C and quenched by addition of brine. The resulting mixture was extracted with DCM (3x). The combined organic phase was concentrated under reduced pressure to give B-3a.

[0347] The following intermediate B-3 (Table 2) can be accessed in an analogous manner: The crude product is purified by chromatography if necessary. [Table 3]

[0348] Experimental procedure for the synthesis of B-4a [ka] (R)-Methyl oxazaborolidine (0.99 g, 3.3 mmol, 0.20 equiv) was dissolved in THF (2 mL) under argon atmosphere and cooled to -5°C. Borane-dimethylsulfide complex (1.0 M, 22 mL 22 mmol, 1.3 equiv) was added. The mixture was stirred at room temperature for 30 min. The mixture was cooled to -5°C and B-3a (4.1 g, 17 mmol, 1 equiv) was added dropwise slowly. The reaction was stirred at room temperature for 1 h. After complete conversion of the starting material, the reaction was cooled to -10°C and quenched by addition of MeOH. The mixture was concentrated under reduced pressure. The residue was dissolved in water (150 mL) and formic acid (0.5 mL) and extracted with DCM (3x). The combined organic phase was concentrated under reduced pressure and purified by NP chromatography to give product B-4a.

[0349] The following intermediate B-4 (Table 3) can be accessed in an analogous manner: The crude product is purified by chromatography if necessary. [Table 4]

[0350] Experimental procedure for the synthesis of B-5a [ka] B-4a (306 mg, 12.5 mmol, 1.00 equiv) was dissolved in THF (30.6 mL) under an argon atmosphere. Lithium aluminum hydride (1 M in THF, 24.9 mL, 25.0 mmol, 2.00 equiv) was added slowly. The reaction was stirred at 60° C. for 1 h. After complete conversion, the reaction was cooled to room temperature and Rochelle's salt solution and KOH were added and stirred for 1 h. The existing suspension was extracted with DCM (3×) and the combined organic phase was concentrated under reduced pressure to yield B-5a.

[0351] The following intermediate B-5 (Table 4) can be accessed in an analogous manner: The crude product is purified by chromatography if necessary. [Table 5]

[0352] Synthesis of pyrimidine derivatives C Experimental procedure for the synthesis of C-3a: [ka] To a stirred solution of 2-methoxy-malonic acid dimethyl ester (36.0 g, 222 mmol, 1.00 equiv.) and thiourea (25.4 g, 333 mmol, 1.50 equiv.) in MeOH (360 mL), sodium methoxide (27.8 g, 555 mmol, 2.5 equiv.) was added at room temperature and the mixture was stirred at 80° C. for 24 h. After complete conversion, iodomethane (41.0 g, 289 mmol, 1.30 equiv.) was added slowly at room temperature and the mixture was stirred at room temperature for 16 h. After complete conversion, the reaction mixture was concentrated, water was added and the reaction mixture was stirred for 30 min. The product was collected by filtration, washed with water and dried under vacuum. The crude product C-3a was used in the next step without purification (HPLC method: H,t ret =0.89 minutes;[M+H] + =189).

[0353] Experimental procedure for the synthesis of C-4a: [ka] To a stirred mixture of C-3a (3.1 g, 16 mmol, 1.0 equiv.) and N,N-diethylaniline (0.4 mL), POCl3 (13 g, 81 mmol, 5.0 equiv.) was slowly added at 0° C., and the resulting mixture was stirred at 90° C. for 16 h. After complete conversion, the mixture was cooled to room temperature, the excess POCl3 was evaporated, water was added, and the product was isolated by extraction with EtOAc. The crude product was purified by NP chromatography to give C-4a (HPLC method: H,tret =2.12 minutes;[M+H] + =225).

[0354] Experimental procedure for the synthesis of C-5a: [ka] To a stirred solution of C-4a (24.0 g, 107 mmol, 1.00 equiv.) in DCM (240 mL) at 0° C., m-CPBA (55.0 g, 321 mmol, 3.0 equiv.) was added, the mixture was allowed to reach room temperature and stirred for an additional 16 h. After complete conversion, the mixture was diluted with DCM, washed with saturated NaHCO3, the organic layer was dried, filtered and concentrated to yield C-5a, which was used in the next step without purification (HPLC method: H, t ret =1.68 minutes;[M+H] + =257).

[0355] Synthesis of nitrile intermediate D Experimental procedure for the synthesis of D-1a: [ka] To a stirred solution of C-5a (24.0 g, 93.4 mmol, 1.0 equiv) in ACN (216 mL) and water (24 mL) under nitrogen at 0° C., NaCN (5.49 g, 112 mmol, 1.2 equiv) was added, the mixture was allowed to reach room temperature and stirred for an additional 1 h. After complete conversion, water and EtOAc were added, the organic layer was separated, washed with water, dried, filtered, concentrated and the crude product was purified by NP chromatography to afford D-1a.

[0356] Synthesis of esters and acids Experimental procedure for the synthesis of E-2a: [ka] 4,6-Dichloropyrimidine-2-carboxylic acid E-1a (900 mg, 4.66 mmol, 1.0 equiv.) was dissolved in DMSO (2 mL) and DIPEA (1.5 mL, 8.8 mmol, 2.0 equiv.) and (S)-tert-butyl 3-methyl-1,4-diazepane-1-carboxylate (1049 mg, 4.896 mmol, 1.05 equiv.) was added dropwise. The reaction mixture was then stirred at 40° C. for 18 h. The mixture was diluted with acetonitrile and purified by acidic RP chromatography to give the desired product E-2a (HPLC method: A,t ret =0.82 minutes, [M+H] + =371).

[0357] Experimental procedure for the synthesis of intermediate E-3a: [ka] D-1a (7.00 g, 34.3 mmol, 1.0 equiv) was added to a stirred solution of HCl (4 M in MeOH, 105 mL, 420 mmol, 12.4 equiv) at 0° C. The mixture was allowed to reach room temperature and stirred for an additional 16 h. After complete conversion, the reaction mixture was concentrated and the crude product was purified by NP chromatography to give the desired product E-3a (HPLC method: H,t ret =1.48 minutes;[M+H] + =237).

[0358] Experimental procedure for the synthesis of intermediate E-5 (Method I): [ka] Methyl 4,6-dichloropyrimidine-2-carboxylate E-4a (3.00 g, 14.5 mmol, 1.0 equiv.) was dissolved in DCM (30 mL) and DIPEA (5.34 mL, 29.0 mmol, 2.0 equiv.) and B-5b (3.20 g, 21.8 mmol, 1.5 equiv.) were added. The reaction mixture was then stirred at room temperature for 18 h. After complete conversion, the mixture was concentrated, water was added, the mixture was extracted with EtOAc, the organic phase was washed with brine, dried, filtered and concentrated. The crude product was purified by NP chromatography to yield E-5a.

[0359] The following intermediate E-5 (Table 5) can be accessed in an analogous manner: The crude product is purified by chromatography if necessary. [Table 6]

[0360] Experimental procedure for the synthesis of intermediate E-5c (Method II): [ka] B-5a (100 mg, 0.48 mmol, 1 equiv) was dissolved in THF (500 μL) and LiHMDS (591 μL, 0.59 mmol, 1.1 equiv) was added and stirred for 5 min. Meanwhile, methyl 4,6-dichloropyrimidine-2-carboxylate E-4a (170 mg, 0.81 mmol, 1.5 equiv) was dissolved in THF (500 μL). The solution of B-5a was added dropwise over 5 min to the methyl 4,6-dichloropyrimidine-2-carboxylate solution. The reaction was stirred for 25 min. After complete conversion, the reaction mixture was filtered and purified by RP chromatography to give E-5c (HPLC method: A,t ret =1.08 minutes, [M+H] + =330).

[0361] Synthesis of diketonesF When multiple HPLC retention times are reported, it is implied that different tautomers exist.

[0362] Experimental procedure for the synthesis of F-1a [ka] 4,6-Dichloropyrimidine-2-carboxylic acid methyl ester E-4a (2.00 g, 9.67 mmol, 1.00 equiv.) was dissolved in dry ACN (5 mL) under nitrogen atmosphere. A solution of magnesium bromide diethyl etherate (2.99 g, 11.6 mmol, 1.20 equiv.), A-6b (2.38 g, 10.6 mmol, 1.10 equiv.) in ACN (5 mL) and DIPEA (2.67 mL, 14.5 mmol, 1.50 equiv.) was added and the reaction mixture was stirred at 50° C. for 20 h. After complete conversion, the reaction mixture was carefully quenched with 1M HCl, diluted with water, extracted with DCM, the organic phase was dried, filtered and concentrated to give crude F-1a. The crude compound was purified by NP chromatography (HPLC method: H,t ret =2.50 minutes; [M+H]=399 / 401).

[0363] Experimental procedure for the synthesis of F-2a [ka] F-1a (10.0 g, 19.4 mmol, 1.00 equiv.) was dissolved in DMSO (10 mL), (1S)-1-[(2S)-1-methylpyrrolidin-2-yl]ethanol (2.76 g, 21.4 mmol, 1.10 equiv.) and DIPEA (6.78 mL, 38.8 mmol, 2.0 equiv.) were added and the solution was stirred at room temperature overnight. The reaction mixture was diluted with DCM and water. The organic phase was separated and evaporated and the resulting residue was purified by RP chromatography to give F-2a (HPLC method: A,t ret =1.58 / 1.66 minutes; [M+H]=492).

[0364] Experimental procedure for the synthesis of F-3a [ka] Under argon atmosphere, E-2a (1.05 g, 2.83 mmol, 1.00 equiv) and 1-(1H-imidazole-1-carbonyl)-1H-imidazole (918 mg, 5.66 mmol, 2.00 equiv) were dissolved in dry THF (5 mL) and stirred at room temperature for 1 h. After complete activation of the acid, a solution of A-6b (1.34 g, 5.98 mmol, 2.00 equiv) and LiHMDS (1.0 M in THF, 5.95 mL, 5.95 mmol, 2.10 equiv) was added to the reaction mixture and washed with dry THF (5 mL). The resulting mixture was stirred at 60 °C overnight. After complete conversion, the reaction was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered and concentrated under reduced pressure to give the crude product. The crude product was dissolved in acetonitrile and water, filtered and purified by basic RP chromatography to give the desired product F-3a (HPLC method: C, t ret =0.888 / 0.936 / 0.978 minutes, [M+H]=557).

[0365] Experimental Procedure for the Synthesis of Intermediate F-4 [ka] E-5c (1.80 g, 0.01 mol, 1.00 equiv) was dissolved in dry THF (18 mL) and activated molecular sieves (3 Å) were added (200 mg per mL of solvent) and stirred at 50° C. for 20 min under argon atmosphere. Magnesium bromide ethyl etherate (2.11 g, 0.01 mol, 1.5 equiv) was then added and stirred at 50° C. for an additional 30 min. Meanwhile, a second solution was prepared using A-6b (1.47 g, 0.01 mol, 1.5 equiv), also predried with activated molecular sieves (3 Å) in THF (8 mL) at 50° C. for 20 min. LiHMDS (1 M in THF, 13.7 mL, 0.01 mol, 2.5 equiv) was then added and stirred for 15 min. The second solution was then added to the first solution and stirred at 50° C. for 1 h until complete conversion to the product was observed. The reaction mixture was carefully quenched with water and THF was removed under reduced pressure. The pH of the residue was adjusted to 7-8 by using 1M HCl and extracted with 5% MeOH in DCM, the combined organic layers were washed with brine, dried, filtered and concentrated. Crude compound F-4a was purified by NP chromatography.

[0366] The following intermediate F-4 (Table 6) can be accessed in an analogous manner: The crude product is purified by chromatography if necessary. [Table 7]

[0367] Synthesis of isoxazole intermediates G Experimental Procedure for the Synthesis of Intermediates G3 and G4 [ka] F-3a (1.10 g, 1.91 mmol, 1.0 equiv) was dissolved in 1,4-dioxane (3 mL) and 50% aqueous hydroxylamine was added (140 μL, 2.29 mmol, 1.2 equiv). The reaction mixture was stirred at room temperature overnight. After complete conversion of the starting material, the reaction was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered, and concentrated under reduced pressure to give the crude product. The crude mixture of G-1a and G-2a (1.00 g, 1.68 mmol, 1.0 equiv) was dissolved in 1,4-dioxane (6 mL) and 4 M aqueous HCl (2.11 mL, 8.44 mmol, 5.0 equiv) was added. The reaction mixture was stirred at room temperature for 3 h. After complete conversion of the starting material was observed, the reaction was diluted with saturated aqueous NaHCO3 and extracted three times with DCM. The organic phases were combined, dried, filtered and concentrated under reduced pressure to give the crude product, which was dissolved in ACN and water, filtered and purified by basic RP chromatography to give the desired product G-3a apart from the corresponding isoxazole regioisomer G-4a.

[0368] The following intermediates G-3 and G-4 (Table 7) are accessible in an analogous manner from the appropriate intermediate F. The crude products are purified by chromatography if necessary. [Table 8]

[0369] Experimental procedure for the synthesis of G-7a [ka] F-4c (1.40 g, 2.68 mmol, 1.0 equiv) was dissolved in dioxane (1 mL) and formic acid (103 μL, 2.95 mmol, 1.10 equiv) and 50% aqueous hydroxylamine (50% in water, 165 μL, 2.95 mmol, 1.10 equiv) were added and stirred overnight. After complete conversion of the starting material was observed, the reaction was concentrated under reduced pressure and purified by NP chromatography to give G-5a (HPLC method: C, t ret =1.60 minutes;[M+H] +=537).

[0370] G-5a (1.60 g, 2.98 mmol, 1.0 equiv) was dissolved in HCl (4 M in dioxane, 2.9 mL) and stirred at room temperature for 5 min. Then, 4 M HCl in water (2.5 mL) was added and the reaction was stirred at room temperature for 30 min. After complete conversion, the reaction mixture was basified with NaHCO3 and extracted with DCM. The combined organic phase was concentrated under reduced pressure to give the product G-7a (HPLC method: H, t ret =1.59 minutes;[M+H] + =537).

[0371] Experimental procedure for the synthesis of G-8a [ka] G-3a (500 mg, 1.07 mmol, 1.0 equiv) was dissolved in dry MeOH (10 mL) and formaldehyde (403 μL, 5.36 mmol, 5.0 equiv) and acetic acid (27 μL, 0.54 mmol, 0.5 equiv) were added. This was followed by the addition of sodium cyanoborohydride (141 mg, 2.14 mmol, 2.0 equiv). The solution was stirred at room temperature for 1 h. After complete consumption of the starting material, the reaction was quenched by the addition of water and saturated NaHCO3. The aqueous phase was extracted with DCM (3×). The combined organic phases were filtered and concentrated under reduced pressure. The residue was dissolved in acetonitrile and purified by RP chromatography to give the desired product G-8a (HPLC method: A,t ret =1.39 minutes;[M+H] + =444).

[0372] Experimental Procedure for the Synthesis of G-9 (Method I) [ka] G-3b (150 mg, 309 μmol, 1.0 equiv), 5-hydroxypyrimidine (44.5 mg, 463 μmol, 1.5 equiv) and Cs2CO3 (201 mg, 617 μmol, 2.0 equiv) were dissolved in dry DMSO (2 mL) and stirred at 80 °C under argon atmosphere for 18 h. After complete conversion, the mixture was diluted with DCM and extracted with water and brine. The combined organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-9a.

[0373] The following intermediate G-9 (Table 8) can be accessed in a similar manner: The crude product is purified by chromatography if necessary. [Table 9]

[0374] Experimental Procedure for the Synthesis of G-9 (Method II) [ka] (S)-(+)-3-hydroxytetrahydrofuran (41.7 mg, 0.45 mmol, 2.0 equiv) was added to a solution of KOtBu / THF (449 μL, 0.45 mmol, 2.0 equiv) at 0° C. and stirred for 5 min. G-3b (100 mg, 0.22 mmol, 1.0 equiv) dissolved in THF (1 mL) was added. The reaction was stirred at room temperature for 5 min. After complete conversion, the reaction mixture was extracted with DCM / water and the organic phase was concentrated under reduced pressure. The residue was purified by RP chromatography to give G-9d.

[0375] The following intermediate G-9 (Table 9) can be accessed in a similar manner: The crude product is purified by chromatography if necessary. [Table 10]

[0376] Experimental Procedure for the Synthesis of G-9g (Method III) [ka] G-3b (250 mg, 272 μmol, 1.0 equiv), 2-hydroxypyrazine (31.3 mg, 326 μmol, 1.2 equiv) and Cs2CO3 (177 mg, 543 μmol, 2.0 equiv) were dissolved in toluene (1 mL) and stirred at 110 °C under argon atmosphere for 18 h. After complete conversion, the reaction mixture was filtered and concentrated under reduced pressure. The residue was dissolved in DCM and extracted with water and brine. The combined organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-9g (HPLC method: A;t ret =1.43 minutes;[M+H] + =505).

[0377] Experimental Procedure for the Synthesis of G-9 and G-10 (Method IV) [ka] G-4b (150 mg, 0.3 mmol, 1.0 equiv), 2-hydroxythiazole (39.4 mg, 0.39 mmol, 1.30 equiv) and t-BuONa (2 M in THF, 210 μL, 0.42 mmol, 1.4 equiv) were dissolved in THF (1.5 mL) and stirred at 80° C. for 18 h. After complete conversion, the reaction mixture was extracted three times with DCM / H2O. The combined organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-10a.

[0378] The following intermediates G-9 and G-10 (Table 10) are accessible in an analogous manner from G-3b and G-4b. The crude products are purified by chromatography if necessary. [Table 11]

[0379] Experimental Procedure for the Synthesis of G-9 and G-10 (Method V) [ka] G-4b (100 mg, 225 μmol, 1.0 equiv), (S)-3-aminotetrahydrofuran (39.0 mg, 448 μmol, 2.0 equiv) and DIPEA (235 μL, 1.35 mmol, 6.0 equiv) were dissolved in dry DMSO (1.0 mL) and stirred at 90° C. for 18 h. The reaction mixture was diluted with DCM and washed with water. The organic phase was dried over magnesium sulfate and evaporated, and the resulting residue was purified by RP chromatography to give G-10d.

[0380] The following intermediates G-9 and G-10 (Table 11) are accessible in an analogous manner from G-3b and G-4b. The crude products are purified by chromatography if necessary. [Table 12]

[0381] Experimental Procedure for the Synthesis of G-9 and G-10 (Method VI) [ka] G-4b (120 mg, 0.27 mmol, 1.0 equiv), 2-aminopyridine (31.7 mg, 0.76 mmol, 1.25 equiv), Xantphos (4.68 mg, 0.01 mmol, 0.03 equiv), Cs2CO3 (131 mg, 0.40 mmol, 1.5 equiv) and tris(dibenzylideneacetone)dipalladium(0) (2.47 mg, 0.26 μmol, 0.01 equiv) were dissolved in dioxane (1.2 mL) and stirred under argon atmosphere at 110 °C for 16 h. After complete conversion, the reaction was filtered and purified by RP chromatography to give the desired product G-10f.

[0382] The following intermediates G-9 and G-10 (Table 12) are accessible in an analogous manner from G-3b and G-4b. The crude products are purified by chromatography if necessary. [Table 13]

[0383] Experimental Procedure for the Synthesis of G-9 (Method VII) [ka] G-3b (125 mg, 0.28 mmol, 1.0 equiv), aminopyrazine (66.8 mg, 702 μmol, 2.5 equiv), Cs2CO3 (275 mg, 0.84 mmol, 3 equiv), palladium(II) acetate (5 mg, 0.02 mmol, 0.08 equiv), (S)-(−)-2,2-bis(diphenylphosphino)-1-binaphthyl (14 mg, 0.02 mmol, 0.08 equiv) were dissolved in dry toluene (5 mL) and stirred at 110° C. for 2 days. After complete conversion, the reaction mixture was allowed to cool to room temperature, filtered, and concentrated under reduced pressure. The reaction was purified by RP chromatography to give the desired product G-9n.

[0384] The following intermediates G-9 and G-10 (Table 13) are accessible in an analogous manner from G-3b and G-4b. The crude products are purified by chromatography if necessary. [Table 14]

[0385] Experimental Procedure for the Synthesis of G-10g (Method VIII) [ka] G-4b (250 mg, 272 μmol, 1.0 equiv), 2-mercaptopyrimidine (50.4 mg, 449 μmol, 2.0 equiv) and Cs2CO3 (145 mg, 449 μmol, 2.0 equiv) were dissolved in dry DMA (0.9 mL) and stirred at 100 °C under argon atmosphere for 3 h. After complete conversion, the reaction mixture was diluted with DCM and extracted with water and brine. The combined organic phase was concentrated under reduced pressure and purified by RP chromatography to give the desired product G-10g (HPLC method: A; t ret =1.53 minutes;[M+H] + =521).

[0386] Experimental procedure for the synthesis of G-9 [ka] G-9h (297 mg, 476 μmol, 1.0 equiv) was dissolved in DCM (0.91 mL) and trifluoroacetic acid (0.99 mL, 4.76 mmol, 10.0 equiv). The reaction was stirred at room temperature for 4 h. After complete conversion, the solvent was removed under reduced pressure. The residue was dissolved in DCM and extracted with saturated aqueous Na2CO3. The combined organic phases were dried, filtered, and concentrated under reduced pressure. The residue was purified by RP chromatography to give G-9s.

[0387] The following intermediates G-9 (Table 14) are accessible in an analogous manner from G-9h and G-9i. The crude products are purified by chromatography if necessary. [Table 15]

[0388] Synthesis of Aminocyanothiophenes H, I, and II Experimental procedure for conversion of G-10 to I [ka] G-10a (52.9 mg, 104 μmol, 1.0 equiv), malononitrile (20 mg, 288 μmol, 2.77 equiv), sulfur (6.2 mg, 193 μmol, 1.86 equiv), beta-alanine (11.9 mg, 127 μmol, 1.22 equiv) and molecular sieves (3 Å) were suspended in methanol (1.0 mL) and stirred at 80° C. for 18 h. The reaction mixture was diluted with DCM, filtered and washed with saturated aqueous NaHCO3. The organic phase was separated and the remaining aqueous phase was extracted with DCM. The combined organic phase was dried over magnesium sulfate and evaporated, and the resulting residue was purified by RP chromatography to give I-1.

[0389] The following compounds I (Table 15) are accessible in an analogous manner from the corresponding ketone G-10. The crude products are purified by chromatography if necessary. [Table 16] TIFF2024543982000087.tif40161

[0390] Experimental procedure for conversion to G-9~II [ka] To a solution of G-9a (75.0 mg, 0.149 mmol, 1.0 equiv.) and molecular sieves (3 Å) in anhydrous methanol (4 mL) under argon atmosphere, malononitrile (20.7 mg, 0.297 mmol, 2.0 equiv.), sulfur (7.15 mg, 0.223 mmol, 1.5 equiv.) and β-alanine (16.7 mg, 0.178 mmol, 1.2 equiv.) were added. The reaction mixture was stirred at 80° C. overnight. After complete conversion, the mixture was cooled to room temperature, filtered and extracted with DCM and saturated aqueous NaHCO3. The organic phases were combined and concentrated under reduced pressure. The residue was dissolved in acetonitrile and water and purified by basic RP chromatography to give the desired product II-1.

[0391] The following compounds II (Table 16) are accessible in an analogous manner from the corresponding ketones G-9. The crude products are purified by chromatography if necessary.

[0392] [Table 17] TIFF2024543982000090.tif243161 TIFF2024543982000091.tif224161

[0393] Experimental procedure for the synthesis of H-1a [ka] To a solution of G-4b (76.1 mg, 0.16 mmol, 1.0 equiv.) and molecular sieves (3 Å) in anhydrous methanol (2 mL) under argon atmosphere, malononitrile (14.5 mg, 0.21 mmol, 1.33 equiv.), sulfur (10.1 mg, 0.31 mmol, 1.98 equiv.) and β-alanine (19.4 mg, 0.22 mmol, 1.38 equiv.) were added. The reaction mixture was stirred at 80° C. overnight. After complete conversion, the mixture was cooled to room temperature, filtered and extracted with DCM and saturated aqueous NaHCO3. The organic phases were combined and concentrated under reduced pressure. The residue was dissolved in acetonitrile and water and purified by basic RP chromatography to give the desired product H-1a (HPLC method: A,t ret =2.16 minutes;[M+H] + =525).

[0394] Experimental procedure for the synthesis of H-2 [ka] G-3c (1.2 g, 2.59 mmol, 1.0 equiv), ammonium acetate (319 mg, 4.15 mmol, 1.6 equiv), and sulfur (133 mg, 4.15 mmol, 1.6 equiv) were dissolved in ethanol (12 mL) and stirred at 60° C. for 15 min. A solution of malonitrile in ethanol (3.77 mL, 4.28 mmol, 1.65 equiv) was slowly added dropwise (8 mL / h). The reaction was stirred at 80° C. for 5 h. After complete conversion, the reaction was concentrated and purified by NP chromatography. The product fraction was diluted with DCM and washed with saturated aqueous NaHCO3. The organic phase was dried, filtered, and concentrated under reduced pressure to give H-2a.

[0395] The following intermediate H-2 (Table 17) can be accessed in a similar manner: The crude product is purified by chromatography if necessary. [Table 18]

[0396] Experimental procedure for the synthesis of II-19 [ka] II-8 (23.0 mg, 0.038 mmol, 1.0 equiv) was dissolved in dry DCM (0.5 mL) under argon and cooled to -30°C. Formaldehyde (37% in water, 3.4 μL, 0.046 mmol, 1.2 equiv) was added followed by sodium triacetoxyborohydride (17.0 mg, 0.076 mmol, 2.0 equiv). The solution was stirred at -30°C for 30 min. After complete consumption of the starting material, the reaction was quenched by addition of water. The aqueous phase was extracted with DCM (3x). The combined organic phases were filtered and concentrated under reduced pressure. The residue was dissolved in acetonitrile and purified by RP chromatography to give the desired product II-19 (HPLC method: A,t ret =1.66 minutes;[M+H] + =618).

[0397] Experimental procedure for the conversion of H-2c to H-II (Method I) [ka] H-2c (100 mg, 0.19 mmol, 1.0 equiv) was suspended in ethanol (0.70 mL). DIPEA (49.8 μL, 0.29 mmol, 1.5 equiv) and N,N,N'-trimethylethylenediamine (29.5 μL, 0.229 mmol, 1.2 equiv) were added and the reaction mixture was stirred at 80 °C overnight. After complete conversion, the reaction mixture was filtered and purified by RP chromatography to give II-20 (HPLC method: A,t ret =1.49 minutes;[M+H] + =591).

[0398] Experimental procedure for the conversion of H-1 and H-2 to I and II (Method II) [ka] [1-(Dimethylamino)cyclopropyl]methanol hydrochloride (34.4 mg, 0.227 mmol, 1.30 equiv) was dissolved in THF (2 mL) and cooled to 0-5 °C. Potassium tert-butoxide (1N in THF, 366 μL, 0.366 mmol, 2.10 equiv) was added dropwise and the reaction mixture was stirred at 0-5 °C for 30 min. H-2c (100 mg, 0.174 mmol, 1.00 equiv) was dissolved in THF (1.0 mL) and added dropwise at 0-5 °C. The reaction mixture was stirred at room temperature for 1 h. HPLC showed about 50% conversion (starting material and byproducts). The reaction mixture was quenched with water and concentrated under reduced pressure. The crude product was purified by RP chromatography to yield II-21 (HPLC method: A, tret = 1.65 min; [M+H] + = 604).

[0399] The following compounds I and II (Table 18) can be obtained in a similar manner. The crude product is purified by chromatography if necessary. [Table 19] TIFF2024543982000099.tif152161

[0400] Experimental procedure for the conversion of H-2 to H-II (Method III) [ka] Tert-Butyl-(3R)-3-hydroxy-2,2-dimethyl-azetidine-1-carboxylate (98.8 mg, 0.476 mmol, 1.10 equiv) was dissolved in THF (3.0 mL). NaH (60% in mineral oil, 36.3 mg, 0.909 mmol, 2.10 equiv) was added and the mixture was stirred at room temperature for 10 min. H-2a (235 mg, 0.433 mmol; 1.0 equiv) was dissolved in dry THF (5 mL) and added to the mixture. The mixture was stirred at room temperature for 1 h. The reaction mixture was quenched with saturated aqueous NH4Cl solution, DCM was added, the organic layer was separated, dried, filtered and evaporated. The crude product was purified by RP chromatography to yield II-26.

[0401] The following compounds II (Table 19) can be accessed in a similar manner: The crude product is purified by chromatography if necessary. [Table 20]

[0402] Experimental procedure for the synthesis of II [ka] II-23 (60.0 mg, 0.087 mmol, 1.0 equiv) was dissolved in TFA (1 mL, 13.4 mmol, 154 equiv) and the reaction was stirred at room temperature for 15 min. After complete conversion, the reaction mixture was concentrated in vacuo and the residue was diluted with DCM, washed with saturated aqueous NaHCO3, dried, filtered and concentrated. The crude product was purified by RP chromatography.

[0403] The following compounds II (Table 20) can be obtained in a similar manner: The crude product is purified by chromatography if necessary. [Table 21]

[0404] The following examples are intended to illustrate the biological activities of the compounds according to the invention, but are not intended to limit the invention.

[0405] KRAS::SOS1 AlphaScreen binding assay This assay can be used to test the potency of compounds according to the invention that bind to (mutated) KRAS to inhibit the protein-protein interaction between SOS1 and (mutated) KRAS, e.g., KRAS WT, KRAS G12C, KRAS G12D, KRAS G12V, KRAS G13D. This inhibits the GEF function of SOS1 and locks the corresponding mutated KRAS protein in its inactive GDP-bound state. Low IC in this assay environment50 The values ​​are indicative of strong inhibition of the protein-protein interaction between SOS1 and KRAS:

[0406] Assay Description: These assays use Alpha Screen technology by Perkin Elmer to measure the inhibitory effect of compounds on mutant KRAS protein-protein interactions.

[0407] The following (mutant) enzymatic forms of KRAS and interacting proteins are used at fixed concentrations in these assays: KRAS(G12D)1-169, N-terminal 6His tag, C-terminal avi tag (Xtal BioStructures, Inc.); final assay concentration 10 nM, and SOS1 564-1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 5 nM; KRAS(G12C)1-169, N-terminal 6His tag cleaved for purification, C-terminal avi tag biotinylated, mutations: C51S, C80L, C118S (in-house); final assay concentration 7.5 nM, and SOS1 564-1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 5 nM; KRAS(G12V)1-169, N-terminal 6His tag to be cleaved for purification, C-terminal avi tag biotinylated, TEV cleavage site, mutation: C118S, GDP loaded (in-house); final assay concentration 10 nM, and SOS1 564-1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 10 nM; KRAS(G13D)1-169, N-terminal 6His tag to be cleaved for purification, C-terminal avi tag biotinylated, TEV cleavage site, mutation: C118S, GDP loaded (in-house); final assay concentration 10 nM, and SOS1 564-1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 10 nM; KRAS (WT) 1-169, N-terminal 6His tag to be cleaved for purification, C-terminal avi tag biotinylated, TEV cleavage site, mutation: C118S, GDP loaded (in-house); final assay concentration 10 nM, and SOS1 564-1049, N-terminal 229 GST tag, TEV cleavage site (Viva Biotech Ltd); final assay concentration 10 nM.

[0408] Test compounds dissolved in DMSO are dispensed into assay plates (Proxiplate 384 PLUS, white, PerkinElmer; 6008289) using an Access Labcyte Workstation equipped with a Labcyte Echo 55x. 150 nL of compound solution is transferred from a 10 mM DMSO compound stock solution for the highest assay concentration chosen of 100 μM. A series of 11 5-fold dilutions per compound are transferred to the assay plate and compound dilutions are tested in duplicate. DMSO is added as a recharge to a total volume of 150 nL.

[0409] The assay is performed on a fully automated robotic system in a dark room at 100 Lux or less. To 150 nl of compound dilution in columns 1-24, add 10 μl of a mixture containing KRAS mutant protein, SOS1 (final assay concentrations see above) and GDP nucleotide (Sigma G7127; final assay concentration 10 μM) in assay buffer (1×PBS, 0.1% BSA, 0.05% Tween 20).

[0410] After a 30 minute incubation period, 5 μl of the Alpha Screen bead mixture in assay buffer is added to columns 1 to 23. The bead mixture consists of AlphaLISA Glutathione Acceptor Beads (PerkinElmer, Cat No AL109) and AlphaScreen Streptavidin Donor Beads (PerkinElmer Cat No 6760002) each at a final assay concentration of 10 μg / ml in assay buffer.

[0411] The plates are kept at room temperature in a darkened incubator. After a further incubation period of 60 minutes, the signal is measured in a PerkinElmer Envision HTS Multilabel Reader using PerkinElmer AlphaScreen specs.

[0412] Each plate contains up to 16 negative control wells (DMSO instead of test compound; with KRAS mutant::SOS1 GDP mix and bead mix; column 23) and 16 positive control wells (DMSO instead of test compound; with KRAS mutant::SOS1 GDP mix but without bead mix; column 24) depending on the dilution procedure (platewise or stepwise).

[0413] As an internal control, a known inhibitor of the KRAS mutant::SOS1 interaction can be tested on each compound plate.

[0414] I C 50 Values ​​are calculated and analyzed with the MEGALAB IC50 application from Boehringer Ingelheim using a four-parameter logistic model.

[0415] IC of exemplary compounds disclosed herein determined using the above assays 50 values ​​(see Table 21).

[0416] [Table 22] TIFF2024543982000105.tif156161

[0417] Generation of Ba / F3 cell model and proliferation assay Ba / F3 cells are obtained from DSMZ (ACC300, Lot17) and grown in RPMI-1640 (ATCC 30-2001) + 10% FCS + 10 ng / mL IL-3 in a 5% CO2 atmosphere at 37°C. Plasmids containing KRASG12 mutants (i.e., G12D, G12C, G12V) are obtained from GeneScript. To generate KRASG12-dependent Ba / F3 models, Ba / F3 cells are transduced with retroviruses containing vectors carrying KRASG12 isoforms. Platinum-E cells (Cell Biolabs) are used for retroviral packaging. Retroviruses are added to Ba / F3 cells. To ensure infection, 4 μg / mL polybrene is added and cells are spinfected. Infection efficiency is confirmed by measuring GFP-positive cells using a cell analyzer. Further culture the cells with an infection efficiency of 10%-20% and start puromycin selection at 1 µg / mL. As a control, use parental Ba / F3 cells to indicate the selection status. Selection is considered successful when the parental Ba / F3 cell culture dies. To evaluate the transforming potential of the KRASG12 mutations, the growth medium is no longer supplemented with IL-3. Ba / F3 cells carrying the empty vector are used as a control. Approximately 10 days before performing the experiment, remove puromycin.

[0418] For proliferation assays, Ba / F3 cells were plated in 384-well plates at 1.5 × 10 3Cells are seeded at 1000 cells / 60 μL. Compounds are added using an Access Labcyte Workstation equipped with a Labcyte Echo 550 or 555 acoustic dispenser. All treatments are performed in technical duplicates. Treated cells are incubated at 37° C., 5% CO2 for 72 hours. AlamarBlue™ (ThermoFisher), a viability stain, is added and fluorescence is measured on a PerkinElmer Envision HTS Multilabel Reader. Raw data is imported and analyzed into Boehringer Ingelheim proprietary software MegaLab (curve fitting based on the program PRISM, GraphPad Inc.).

[0419] IC of representative compounds according to the present invention measured in this assay 50 The values ​​are presented in Table 23.

[0420] [Table 23]

[0421] Additional proliferation assays using mutant cancer cell lines NCI-H358 CTG proliferation assay (120 hours) (NSCLC, G12C) NCI-H358 cells (ATCC No. CRL-5807) are dispensed into black 384-well plates, flat clear bottom (Greiner, PNr. 781091) at a density of 200 cells / well in 60 μl of RPMI-1640 ATCC-Formulation (Gibco # A10491) + 10% FCS (fetal calf serum). Cells are incubated overnight at 37°C in a humidified tissue culture incubator with 5% CO2. Compounds (10 mM stock in DMSO) are added in a log dose series using an ECHO acoustic liquid handler system (Beckman Coulter) and normalized to added DMSO, and a DMSO control is included. For TO time point measurements, untreated cells are analyzed at the time of compound addition. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as a percentage of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0422] NCI-H2122 CTG proliferation assay (120 hours) (NSCLC, G12C) The CTG assay is designed to quantitatively measure the proliferation of NCI-H2122 cells (ATCC CRL-5985) using the CellTiter Glow Assay Kit (Promega G7571). Cells are grown in RPMI medium (ATCC) supplemented with fetal bovine serum (Life Technologies, Gibco BRL, Cat. No. 10270-106). On "day 0", 200 NCI-H2122 cells are seeded in 60 μL of RPMI ATCC+10% FCS+Penstrep in a black 384-well plate, flat clear bottom (Greiner, PNr. 781091). Cells are then incubated overnight in the plate at 37° C. in a CO2 incubator. On day 1, compounds (10 mM stock in DMSO) are added with an ECHO acoustic liquid handler system (Beckman Coulter) and a DMSO control is included. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as percent of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0423] ·AsPC-1 CTG proliferation assay (120 hours) (pancreatic cancer, G12D) The CTG assay is designed to quantitatively measure the proliferation of AsPC-1 cells (ATCC CRL-5985) using the CellTiter Glow Assay Kit (Promega G7571). Cells are grown in RPMI medium (ATCC) supplemented with fetal bovine serum (Life Technologies, Gibco BRL, Cat. No. 10270-106). On "day 0", 2000 AsPC-1 cells are seeded in 60 μL of RPMI ATCC+10% FCS+Penstrep in a 384-well plate, flat clear bottom (Greiner, PNr. 781091). The cells are then incubated overnight in the plate at 37° C. in a CO2 incubator. On day 1, compounds (10 mM stock in DMSO) are added with an ECHO acoustic liquid handler system (Beckman Coulter) and a DMSO control is included. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as percent of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0424] ·GP2D proliferation assay (120 hours) (Colon cancer, G12D) GP2D cells (ATCC No. CRL-5807) are dispensed into white 384-well plates, flat white bottom (Perkin Elmer, 6007680) at a density of 500 cells / well in 40 μl of DMEM (Sigma, D6429) + 1× GlutaMAX (Gibco, 35050038) + 10% FCS (fetal calf serum). Cells are incubated overnight at 37° C. in a humidified tissue culture incubator with 5% CO2. Compounds (10 mM stock in DMSO) are added in a log dose series using an HP Digital Dispenser D300 (Tecan), DMSO controls are included and normalized to added DMSO. For TO time point measurements, untreated cells are analyzed at the time of compound addition. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as a percentage of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0425] SAS CTG proliferation assay (120 hours) (HNSCC, amplified wt) SAS cells (JCRB0260) are dispensed into 384-well plates, flat clear bottom (Greiner, PNr. 781091) at a density of 300 cells / well in 60 μL of DMEM:F12 (Gibco 31330-038) + 10% fetal bovine serum (HyClone, PNr.:SH30084.03) and incubated overnight at 37 °C in a CO2 incubator. The following day, compounds (10 mM stock in DMSO) are added with an ECHO acoustic liquid handler system (Beckman Coulter) and a DMSO control is included. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as a percent of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. I C 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0426] ·MKN1 CTG proliferation assay (120 hours) (gastric cancer, amplified wt) MKN1 cells (JCRB0252) are dispensed into white 384-well plates, flat white bottom (Perkin Elmer, 6007680) at a density of 500 cells / well in 40 μl RPMI (Gibco, PNr.:21875034)+10% FCS (HyClone, PNr.:SH30084.03) (Assay 1) or into black 384-well plates, flat clear bottom (Greiner, PNr. 781091) at a density of 200 cells / well in 60 μl RPMI-1640 (Gibco # A10491)+10% FCS (HyClone, PNr.:SH30084.03)+PenStrep (Gibco, PNr.15140-122) (Assay 2). Cells are incubated overnight at 37°C in a humidified tissue culture incubator with 5% CO2. Compounds (10 mM stock in DMSO) are added in a log dose series using an HP Digital Dispenser D300 (Tecan) (assay 1) or an ECHO acoustic liquid handler system (Beckman Coulter) (assay 2), a DMSO control is included and normalized to added DMSO. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as a percent of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0427] ·SK-CO-1 CTG proliferation assay (120 hours) (CRC, G12V) SK-CO-1 cells (ATCC HTB-39) are dispensed into 384-well plates, flat clear bottom (Greiner, PNr. 781091) at a density of 500 cells / well in 60 μL of EMEM (Sigma M5650) + 10% fetal bovine serum (HyClone, PNr.:SH30084.03) and incubated overnight at 37 °C in a CO2 incubator. The following day, compounds (10 mM stock in DMSO) are added with an ECHO acoustic liquid handler system (Beckman Coulter) and a DMSO control is included. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as a percent of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50 Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0428] LOVO CTG proliferation assay (120 hours) (CRC, G13D) LOVO cells (ATCC CCL-229) are dispensed into 384-well plates, flat clear bottom (Greiner, PNr. 781091) at a density of 1000 cells / well in 60 μL of DMEM (Sigma D6429) + 10% fetal bovine serum (HyClone, PNr.:SH30084.03) and incubated overnight at 37 °C in a CO2 incubator. The following day, compounds (10 mM stock in DMSO) are added with an ECHO acoustic liquid handler system (Beckman Coulter) and a DMSO control is included. Plates are incubated for 120 hours and cell viability is measured using CellTiter-Glo Luminescent Cell Viability Reagent (Promega product code G7570). Viability (defined as a percent of control) is defined as the relative luminescence units (RLU) of each well divided by the RLU of cells in the DMSO control. IC 50Values ​​are determined from viability measurements by non-linear regression using a four-parameter model.

[0429] IC of representative compounds of the present invention measured in these assays in the indicated cell lines. 50 The values ​​are presented in Tables 22 and 23.

[0430] [Table 24] TIFF2024543982000108.tif146161

[0431] [Table 25]

[0432] ERK phosphorylation assay The ERK phosphorylation assay is used to examine the efficacy of the compounds to inhibit KRAS G12C-mediated signaling in KRAS G12C mutant human cancer cell lines in vitro. This demonstrates the molecular mechanism of action of the compounds of the present invention by interfering with the RAS G12C protein signaling cascade. The low IC 50 The values ​​are indicative of the high potency of the compounds of the present invention. It was observed that the compounds of the present invention demonstrate an inhibitory effect on ERK phosphorylation in KRAS G12C mutant human cancer cell lines, thus proving the molecular mechanism of action of the compounds on RAS G12C protein signaling.

[0433] The ERK phosphorylation assay is performed using the following human cell lines:

[0434] NCI-H358 (ATCC (ATCC CRL-5807): human lung cancer with KRAS G12C mutation (→ Assay 1) and NCI-H358_Cas9_SOS2, the same cell line in which SOS2 was knocked out (→ Assay 2). Vectors containing DNA sequences designed for gRNA production for SOS2 protein knockout are obtained from Sigma-Aldrich. To generate NCI-H358 SOS2 knockout cell lines, NCI-H358 cells expressing Cas9 endonuclease are transfected with XtremeGene9 reagent and the corresponding plasmid. Transfection efficiency is confirmed by measuring GFP-positive cells using a cell analyzer. GFP-positive cells are collected and further expanded. These GFP-positive cell pools are subjected to single cell dilution and SOS2 knockout clones are identified via Western blot and genomic DNA sequence analysis.

[0435] Materials used in the assay: RPMI-1640 medium (ATCC® 30-2001™) Fetal bovine serum (FBS), HyClone (SH30071.03) Non-essential amino acids, Thermo Fischer Scientific (11140035) Pyruvate, Thermo Fischer Scientific (11360039) Glutamax, Thermo Fischer Scientific (35050061) 384 plate, Greiner Bio-One (781182) Proxiplate™ 384, PerkinElmer Inc. (6008280) AlphaLISA SureFire Ultra p-ERK1 / 2(Thr202 / Tyr204) Assay Kit(ALSU-PERK-A500) EGF, manufactured by Sigma (E4127) Acceptor Mix: Protein A Acceptor Beads, PerkinElmer (6760137M) Donor Mix: AlphaScreen Streptavidin-coated Donor Beads, manufactured by PerkinElmer (6760002) Trametinib Staurosporine, Sigma Aldrich (S6942)

[0436] Assay Setup: Cells are seeded at 40,000 cells / well in 60 μL of RPMI containing 10% FBS, non-essential amino acids, pyruvate and glutamax in a Greiner TC 384 plate. Cells are incubated at room temperature for 1 hour, then incubated overnight in an incubator at 37° C. and 5% CO2 in a humidified atmosphere. Then, 60 nL of compound solution (10 mM DMSO stock solution) is added using a Labcyte Echo 550 device. After 1 hour of incubation in the aforementioned incubator, the medium is removed after centrifugation, and the cells are lysed by adding 20 μL of 1.6x lysis buffer from the AlphaLISA SureFire Ultra pERK1 / 2 (Thr202 / Tyr204) Assay Kit, and protease inhibitors, 100 nM trametinib + 100 nM staurosporine, are added. After 20 min incubation at room temperature with shaking, 6 μL of each lysate is transferred to a 384-well Proxiplate and pERK(Thr202 / Tyr204) is analyzed with the AlphaLISA SureFire Ultra pERK1 / 2(Thr202 / Tyr204) Assay Kit. 3 μL of Acceptor Mix and 3 μL of Donor Mix are added in dim light and incubated at room temperature in the dark for 2 h before measuring the signal with a PerkinElmer Envision HTS Multilabel Reader. Raw data is imported and analyzed into Boehringer Ingelheim proprietary software MegaLab (curve fitting based on the program PRISM, GraphPad Inc.).

[0437] Similarly, the assays described (pERK reduction; SureFire) can be performed in additional cell lines carrying various KRAS mutations or KRAS wild type to measure and determine the activity of compounds against various additional KRAS alleles in the cellular background.

[0438] Metabolic (microsomal) stability assay The metabolic degradation of test compounds is assayed at 37°C using pooled liver microsomes (mouse (MLM), rat (RLM) or human (HLM)). A final incubation volume of 48 μL per time point contains TRIS buffer (pH 7.5; 0.1 M), magnesium chloride (6.5 mM), microsomal protein (0.5 mg / mL for mouse / rat and 1 mg / mL for human samples) and a final concentration of 1 μM of test compound. Following a short preincubation period at 37°C, the reaction is initiated by adding 12 μL of beta-nicotinamide adenine dinucleotide phosphate, reduced form (NADPH, 10 mM) and terminated by transferring aliquots to solvent after various time points (0, 5, 15, 30, 60 min). Additionally, NADPH-independent degradation is monitored by incubation without NADPH and terminated by adding acetonitrile at the final time point. The quenched incubations are pelleted by centrifugation (4,000 rpm, 15 min.) and an aliquot of the supernatant is assayed by LC-MS / MS to quantitate the concentration of parent compound in each sample.

[0439] In vitro intrinsic clearance (CL int、インビトロ ) is calculated from the time course of disappearance of the test drug during microsomal incubation. Each plot is divided into two parts, C(t) = C0 * exp(-ke * t), where C(t) and C0 are the unchanged test drug concentrations at incubation time t and preincubation, and ke is the elimination rate constant for the unchanged drug. Then, CL int、インビトロ (μL min -1 The protein amount) value was calculated from the incubation parameters using the equation CL int、インビボ =CL int、インビトロ Predicted CL according to: × (incubation volume (ml) / protein amount (mg)) × (protein amount (mg) / liver tissue g) × (liver weight / body weight) int,インビボ (mL min -1 ·kg -1 )

[0440] For better interspecies comparison, predicted clearance was expressed as percent hepatic blood flow [% QH] (mL min -1 ·kg -1 ) Generally, high compound stability across species (corresponding to low % QH) is desirable.

[0441] Table 24 shows metabolic stability data obtained in the disclosed HLM assay for a selection of compounds (I) according to the invention.

[0442] [Table 26]

[0443] Plasma Protein Binding Assay (PPB) Binding of test compounds to plasma was determined using equilibrium dialysis (ED) and liquid chromatography coupled with quantitative mass spectrometry (LC-MS). Briefly, ED was performed using a dialysis device consisting of two chambers separated by a semipermeable membrane with a molecular weight cutoff of 5-10 kg / mol. One chamber was filled with 10% FCS in PBS containing 1-10 μmol / L of test compound, and the other chamber was filled with phosphate-buffered saline (PBS) with or without dextran. The dialysis chambers were incubated at 37°C for 3-5 h. After incubation, proteins were precipitated from an aliquot of each chamber and the plasma-containing compartment (c serum ) and a compartment containing a buffer (c buffer The concentration of test compound in the supernatant of each sample was determined by LC-MS. The fraction of unbound test compound (not bound to plasma) (f u ) was calculated according to the following equation:

number

[0444] Table 25 shows metabolic stability data obtained in the disclosed assays for a selection of compounds (I) according to the invention.

[0445] [Table 27]

[0446] Mechanism-based CYP3A4 Inhibition Assay (MBI 3A4): Time-dependent inhibition of CYP3A4 is assayed in human liver microsomes (0.02 mg / mL) using midazolam (15 μM) as substrate. Test compounds and water controls (wells without test compound) are preincubated with human liver microsomes (0.2 mg / mL) in the presence of NADPH (1 mM) at a concentration of 25 uM for 0 and 30 min. After preincubation, the incubation is diluted 1:10 and the substrate midazolam is added to the main incubation (15 min). The main incubation is quenched with acetonitrile and the formation of hydroxy-midazolam is quantified via LC / MS-MS. The formation of hydroxy-midazolam from the 30 min preincubation versus the 0 min preincubation is used as readout. Values ​​less than 100% mean that the substrate midazolam is metabolized to a lower extent during the 30 min preincubation compared to the 0 min preincubation. In general, a low effect upon 30 min preincubation is desirable (corresponding to values ​​close to 100% / no difference from values ​​determined with the water control).

[0447] Table 26 shows the data obtained in the disclosed assays for a selection of compounds (I) according to the invention.

[0448] [Table 28]

[0449] Solubility measurement (DMSO solution precipitation method) A 10 mM DMSO stock solution of the test compound is used to determine its aqueous solubility. The DMSO solution is diluted in aqueous medium (McIlvaine buffer, pH=4.5 or 6.8) to a final concentration of 250 μM. After shaking for 24 hours at ambient temperature, any precipitate that may have formed is removed by filtration. The concentration of the test compound in the filtrate is determined by LC-UV method by calibrating the signal against that of a reference solution using complete dissolution of the test compound in acetonitrile / water (1:1) of known concentration.

[0450] Table 27 shows data obtained in the disclosed assays for a selection of compounds (I) according to the invention.

[0451] [Table 29]

[0452] Caco-2 assay This assay provides information on the ability of compounds to cross cell membranes, the extent of oral absorption, and whether compounds are actively transported by uptake and / or efflux transporters. It uses permeability measurements across polarized confluent Caco-2 cell monolayers grown on permeable filter supports (Corning, catalog #3391). A 10 μM solution of test compound in assay buffer (128.13 mM NaCl, 5.36 mM KCl, 1 mM MgSO4, 1.8 mM CaCl2, 4.17 mM NaHCO3, 1.19 mM Na2HPO4, 0.41 mM NaH2PO4, 15 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 20 mM glucose, pH 7.4) is added to the donor compartment of a cell chamber containing a monolayer of Caco-2 cells between the donor and receiver compartments. The receiver and donor compartments contain 0.25% bovine serum albumin (BSA) in assay buffer. Passive diffusion and / or active transport of compounds across the monolayer are measured in both apical to basolateral (ab) and basolateral to apical (ba) directions. Ab permeability (PappAB) represents drug absorption from the intestine to the blood via both passive permeation and active transport mechanisms mediated by efflux and uptake transporters expressed on Caco-2 cells, whereas ba permeability (PappBA) represents drug secretion from the blood back to the intestine. After preincubation at 37°C for 25-30 min, samples were taken from the receiver and donor compartments, respectively, at predefined time points (0, 30, 60 and 90 min). The concentration of the test compound in the samples was measured by HPLC / MS / MS, with samples from the donor compartment diluted 1:50 (v:v) in assay buffer and samples from the receiver compartment measured undiluted.

[0453] The apparent permeability in the two directions ab (PappAB) and ba (PappBA) is calculated according to the following formula:

number

[0454] The Caco-2 efflux ratio (ER) is calculated as the ratio of PappBA / PappAB.

[0455] Table 28 shows data obtained in the disclosed assays for a selection of compounds (I) according to the invention.

[0456] [Table 30]

[0457] The following formulation examples are illustrative of the present invention but are not intended to limit its scope:

[0458] Examples of pharmaceutical prescriptions [Table 31]

[0459] The finely ground active substance, lactose and some of the corn starch are mixed. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and magnesium stearate are screened and mixed. The mixture is compressed to produce tablets of suitable shape and size.

[0460] [Table 32]

[0461] The finely ground active substance, a portion of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed, the mixture is sieved, the remaining corn starch and water are treated to produce granules, which are dried and sieved, sodium carboxymethyl starch and magnesium stearate are added, mixed and the mixture is compressed to produce tablets of suitable size.

[0462] [Table 33]

[0463] The active substance, lactose and cellulose are mixed. The mixture is screened, then moistened with water, kneaded, wet granulated, dried or dry granulated, or final blended directly with magnesium stearate and compressed to tablets of suitable shape and size. If wet granulated, additional lactose or cellulose and magnesium stearate are added and the mixture is compressed to produce tablets of suitable shape and size.

[0464] [Table 34]

[0465] The active substance is dissolved in water at its own pH or optionally at pH 5.5-6.5, and sodium chloride is added to make it isotonic. The resulting solution is filtered to make it pyrogen-free, and the filtrate is transferred under aseptic conditions into ampoules, which are then sterilized and melt-sealed. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

Claims

1. Formula (I): 【Chemistry 1】 [In the formula, R 1a and R 1b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; R 2a and R 2b are each independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; and / or optionally, R 1a Or R 1b One of the two and R 2a Or R 2b together with the carbon atom to which they are attached form a cyclopropane ring; Z is -(CR 6a R 6b ) n - and Each R 6a and R 6b are independently hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 selected from the group consisting of cycloalkyl and 3-5 membered heterocyclyl; Or, R 6a and R 6b together with the carbon atoms to which they are attached form a cyclopropane ring; n is selected from the group consisting of 0, 1 and 2; L is -O-, -S-, or -N(R 7 )-(wherein, R 7 is hydrogen or C 1-6 alkyl; R 3 is C 1-6 Alkyl, C 1-6 alkoxy, 5- to 10-membered heteroaryl, and 3- to 11-membered heterocyclyl, wherein C 1-6 Alkyl, 5-10 membered heteroaryl, C 1-6 All alkoxy and 3- to 11-membered heterocyclyl are optionally and independently selected from the same or different halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -OH, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , -C(O)O-C 1-6 Alkyl, C 3-5 Cycloalkyl, or -N(C 1-4 Alkyl) 2 substituted by 3- to 11-membered heterocyclyl optionally substituted by W is nitrogen (-N=) or -CH=; V is nitrogen (-N=) or -CH=; U is nitrogen (-N=) or -C(R 11 ) =; R 11 is hydrogen, halogen and C 1-4 alkoxy; Ring A is a ring selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, and triazole; Each R 4 is, if present, independently 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, Cyano-C 1-6 Alkyl, halogen, -OH, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , -C.N., C. 3-5 selected from the group consisting of cycloalkyl and 3- to 5-membered heterocyclyl; p is selected from the group consisting of 0, 1, 2 and 3; R 5 is one or more of the same or different, C 1-6 Alkyl, C 1-6 3- to 11-membered heterocyclyl optionally substituted with alkoxy or 5- to 6-membered heterocyclyl, where C 1-6 alkyl is optionally substituted with cyclopropyl; Or, R 5 is —O—C substituted with 3- to 11-membered heterocyclyl 1-6 alkyl, where the 3- to 11-membered heterocyclyl is one or more of the same or different R 12 and optionally substituted with Each R 12 is C 1-6 Alkyl, C 1-6 selected from the group consisting of alkoxy, halogen and 3- to 11-membered heterocyclyl. or a salt thereof.

2. Formula (Ia): 【Chemistry 2】 [In the formula, A, V, U, W, L, R 3 and R 5 is defined as in claim 1. or a salt thereof.

3. Formula (Ib): 【Chemistry 3】 [In the formula, A, V, U, W, L, R 3 and R 5 is defined as in claim 1. or a salt thereof.

4. Ring A is 【Chemistry 4】 The compound or salt according to any one of claims 1 to 3, selected from:

5. R 5 but, 【Chemistry 5】 The compound or salt according to any one of claims 1 to 4, selected from the group consisting of:

6. R 5 but, 【Chemistry 6】 6. The compound or salt of claim 5, selected from the group consisting of:

7. W is nitrogen (-N=); V is nitrogen (-N=); U is =C(R 11 )—wherein R 11 is hydrogen, halogen and C 1-4 7. The compound or salt according to any one of claims 1 to 6, wherein said aryl group is selected from alkoxy.

8. R 3 But, C 1-6 Alkyl, C 1-6 alkoxy, 5- to 6-membered heteroaryl, and 4- to 5-membered heterocyclyl, wherein C 1-6 Alkyl, 5-6 membered heteroaryl, C 1-6 Alkoxy and 4- to 5-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -OH, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , -C(O)O-C 1-6 Alkyl, C 3-5 Cycloalkyl, or -N(C 1-4 Alkyl) 2 8. The compound or salt of claim 1, which is substituted with 3- to 11-membered heterocyclyl optionally substituted with:

9. R 3 But, C 1-6 Alkyl, C 1-6 is selected from the group consisting of alkoxy, 5- to 6-membered heteroaryl, and 4- to 5-membered heterocyclyl, each of which independently contains 1 or 2 nitrogen or 1 oxygen heteroatoms, where C 1-6 Alkyl, 5-6 membered heteroaryl, C 1-6 Alkoxy and 4- to 5-membered heterocyclyl are all optionally and independently selected from the same or different halogen, C 1-6 Alkyl, C 1-6 Alkoxy, -OH, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , -C(O)O-C 1-6 Alkyl, C 3-5 Cycloalkyl, or -N(C 1-4 Alkyl) 2 9. The compound or salt of any one of claims 1 to 8, which is substituted with 3- to 11-membered heterocyclyl optionally substituted with:

10. R 3 is 4- to 7-membered heterocyclyl or C 3-5 -C substituted with cycloalkyl 1-4 alkyl, where 4-7 membered heterocyclyl is —N(C 1-4 Alkyl) 2 10. The compound or salt of any one of claims 1 to 9, optionally further substituted with:

11. R 3 But, C 1-6 Alkyl, -CH(CH 3 ) CH 2 -O-CH 3 , -(CH 2 ) 2 -O-CH 3 , -(CH 2 ) 2 -OH and -(CH 2 ) 2 -N-(CH 3 ) 2 or R 3 but, 【Chemistry 7】 is a ring selected from the group consisting of wherein each of these rings optionally and independently comprises one or more of the same or different halogen, C 1-6 Alkyl, -OH, -NH 2 , -NH(C 1-4 alkyl), -N(C 1-4 Alkyl) 2 , C 3-5 10. The compound or salt of any one of claims 1 to 9, which is substituted with cycloalkyl or 3- to 11-membered heterocyclyl.

12. R 3 But, C 1-6 Alkyl, -CH(CH 3 ) CH 2 -O-CH 3 , -(CH 2 ) 2 -O-CH 3 , -(CH 2 ) 2 -OH, -(CH 2 ) 2 -N-(CH 3 ) 2 , 【Chemistry 8】 The compound or salt according to any one of claims 1 to 9, selected from the group consisting of:

13. 13. A compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of cancer.

14. 14. The compound or a pharma- ceutically acceptable salt thereof for use according to claim 13, administered in combination with one or more other pharmacologically active substances.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, and one or more other pharmacologically active substances.

Citation Information

Patent Citations

  • Inhibitor of krasg12c

    JP2016532656A

  • Heterocyclic spiro compounds and methods of use for treating cancer

    JP2021532157A

  • Spiro-substituted pyrimidine-fused cyclic compound, preparation method therefor and medical use thereof

    WO2020177629A1

  • KRAS g12c inhibitors and uses thereof

    WO2020236940A1

  • Spirocyclic tetrahydroquinazolines

    WO2021139748A1

Cited By

  • Fused 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer

    JP2024543983A